Abstract
Hepatocellular carcinoma (HCC) was the fifth leading cause of cancer death in men and eighth leading cause of death in women in the United States in 2017. In our study, we sought to identify sncRNAs in various stages of development of HCC. We obtained publicly available small RNA-seq data derived from patients with cirrhosis (n = 14), low-grade dysplastic nodules (LGDN, n = 9), high grade dysplastic nodules (HGDN, n = 6), early hepatocellular carcinoma (eHCC, n = 6), and advanced hepatocellular carcinoma (HCC, n = 20), along with healthy liver tissue samples (n = 9). All samples were analyzed for various types of non-coding RNAs using PartekFlow software. We remapped small RNA-seq to miRBase to obtain differential expressions of miRNAs and found 87 in cirrhosis, 106 in LGDN, 59 in HGDN, 80 in eHCC, and 133 in HCC. Pathway analysis of miRNAs obtained from diseased samples compared to normal samples showed signaling pathways in the microRNA dependent EMT, CD44, and others. Additionally, we analyzed the data sets for piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs. We validated the in silico data using human HCC samples with NanoString miRNA global expression. Our results suggest that publically available data is a valuable resource for sncRNA identification in HCC progression (FDR set to <0.05 for all samples) and that a data mining approach is useful for biomarker development.
Introduction
Hepatocellular carcinoma (HCC) was the fifth leading cause of cancer death in men and eighth leading cause of death in women in the United States in 2017. The incidence of HCC has been increasing every year, with an estimated 40,710 new cases in 20171. In addition, death rates are increasing by 3% every year, with an estimated 28,920 deaths in 20171. These statistics suggest more research needs to be done towards understanding the biology, diagnosis, and prevention. Primary liver cancer, or HCC can be triggered by ongoing inflammation from pathologies such as cirrhosis, dysplastic nodule formation, viral infections (i.e. viral hepatitis), and NASH. Cirrhosis is a condition in which the liver becomes scarred secondary to repeated insults.
HCC often originates in a focus of dysplasia within a cirrhotic regenerative nodule. With progression to more severe dysplasia, the lesion assumes increasingly malignant characteristics until it becomes frankly cancerous. Tumors may be well differentiated or poorly differentiated. As expected, poorly differentiated HCC has a more aggressive course and poorer outcomes than well differentiated HCC.
Scientific progress in next generation sequencing (NGS) has enhanced our understanding of biological systems by profiling whole transcriptomic expression at a molecular level2. Small RNAs are small non-coding RNAs (sncRNA) consisting of 17–250 nucleotides in length that perhaps play a crucial role in disease development3. A nearly comprehensive repertoire of various types of sncRNAs has been collected and analyzed including: microRNA (miRNAs, 17–22 nucleotides)4, piwi-interacting RNAs (piRNAs, 26–33 nucleotides)5, small nuclear/nucleolar RNAs (sn/snoRNAs, 70–120 nucleotides), long non-coding RNAs (lncRNAs, more than 200 nucleotides)6, and circular RNAs (circRNA)7. This has led to great interest in revealing their role in transcriptional regulation. piRNAs are the largest class of the small non-coding RNA family and are implicated in epigenetic and post-transcriptional regulation but still lack functional characterization8. lncRNAs are a diverse class of RNAs, believed to have an important role in cellular mechanisms; however, little biological relevance has been established thus far9. circRNAs are a recently rediscovered class of non-coding RNAs, which were initially described as scrambled exons10,11. They are resistant to endonuclease treatment and are highly stable12. snoRNAs are perhaps the most ancient and highly conserved class of sncRNAs carrying out a fundamental role in modification and processing of ribosomal RNAs (rRNA), transfer RNAs (tRNA), and small nuclear RNAs (snRNA)13. Two well-known classes of snoRNAs are C/D snoRNAs and box H/ACA snoRNAs which primarily differ in sequence and structure13.
The present study focused on in-depth analysis of small RNA sequencing data obtained from cirrhosis, low-grade dysplastic nodules (LGDN), high-grade dysplastic nodules (HGDN), early stage hepatocellular carcinoma (eHCC), and advanced stage hepatocellular carcinoma (HCC). Tissue samples were compared to healthy liver tissue. We aimed to identify the differential signature and dysregulated expression of small non-coding RNAs. We further identified the most predominantly expressed non-coding RNAs and molecular pathways that could serve as biomarkers during malignant transformation.
Materials and Methods
Read Alignment and Annotations
Healthy (BioProject: PRJNA266511) and diseased liver (BioProject: PRJEB11462) small RNA sequencing raw sample datasets14 were downloaded from NIH short read archive (SRA). The datasets contained 14 cirrhosis, 9 low-grade dysplastic nodules, 6 high-grade dysplastic nodules, 6 early HCC, and 20 advanced HCC samples along with 9 healthy liver tissue samples (normal clinical assessment and normal liver enzymes). Downloaded SRA files were converted to FASTQ files using the SRA toolkit version 2.5.715. The FASTQ files were uploaded to PartekFlow® software, version 6.0 (Partek, Inc., St. Louis, MO) on a Linux based High Performance Computing system at Pennsylvania State University College of Medicine, adapter-trimmed, and remapped to human genome hg19 using BWA-0.7.12 aligner (BWA-MEM) with a few modifications (mismatch penalty 2, gap open penalty 6, clipping penalty 4, and alignment score cutoff 15) for short read mapping2,16. miRBase version 20 (http://www.mirbase.org/), which contains more than 1900 high confidence miRNAs17 was used for annotation. piRNA data was generated and annotated from piRBase (http://regulatoryrna.org/database/piRNA), which is manually curated with a focus on functional analysis18. lncRNAs were quantified using reference annotation LNCipedia (http://www.lncipedia.org) version 3.1, downloaded from all coordinates relative to the hg19 reference genome19. circRNA database (http://www.circbase.org) contains thousands of circRNAs and annotation was download and quantified20. Total small RNA (including miRNA, piRNA, snRNA, snoRNA, mt-RNA, tRF3, tRF5, tRNA, and rRNA) was annotated using Gencode version 26 (www.gencodegenes.org)21, which provides comprehensive information on human sncRNAs. Transcript abundances were determined and expression levels were represented using normalized reads per million (RPM) values. All small RNAs with expression RPM values > 1 in 100% of the samples were considered robustly expressed and used for further analysis. Expression matrices were compared among clinicopathological features including cirrhosis, low-grade dysplastic nodules, high-grade dysplastic nodules, early stage HCC, and advanced stage HCC samples2. Statistical analyses were carried out using the non-parametric Mann-Whitney U test followed by false discovery rate (FDR) correction through the Benjamini-Hochberg method. A default FDR < 0.05 was considered statistically significant22 with a log2-fold change more than 1. Circos plots23 were generated for differential expression of all small RNAs in various stages of liver disease.
HCC and Normal Liver Tissue Samples
Hepatocellular carcinoma (n = 3; moderately to poorly differentiated) and normal liver tissue (n = 3; adenoma) frozen samples were obtained from the Institute for Personalized Medicine (IPM) at Penn State College of Medicine, Hershey, PA, after written approval. Total RNA was extracted using a Direct-zol™ RNA Kit (Zymo Research, cat#: R2051) according to the manufacturer’s instructions. The extracted RNAs were quantified and quality checked using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and a BioAnalyzer RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA).
MicroRNA Profiling Using NanoString nCounter miRNA Assays
Total RNA samples were analyzed according to manufacturer’s instructions for the nCounter miRNA Expression Assay kit (NanoString Technologies®, Seattle, WA). Briefly, 100 ng of each sample total RNA was used for nCounter Human miRNA sample preparation. Hybridization was conducted for 16 h at 65°C. Subsequently, probes were purified and counted on the nCounter Prep Station. Each sample was scanned for 600 FOV (fields of view) on the nCounter Digital Analyzer. Data was extracted using the nCounter RCC Collector.
NanoString nCounter miRNA Data Analysis
For platform validation using synthetic oligonucleotides, NanoString nCounter miRNA raw data was normalized for lane-to-lane variation with a dilution series of six spike-in positive controls using nSolver v4.0 software (www.nanostring.com/products/nSolver). The sum of the six positive controls for a given lane were divided by the average sum across lanes to yield a normalization factor, which was then multiplied by the raw counts in each lane to obtain normalized values. For each sample, the mean plus two times the standard deviation of the eight negative controls were subtracted from each miRNA count in that sample. Only miRNAs with non-negative counts across all samples were retained for downstream analysis. The relative miRNA levels were indicated as median fold changes and a cutoff of two fold-change (up or down) was used24. A Venn diagram was prepared using FunRich 3.1.3 open source software25,26.
Biological Processes and Gene Network Visualization by MetaCore
Biological pathway interactions of microRNA expressions were analyzed using MetaCore pathway analysis of differentially expressed genes (Thomson Reuters, New York, NY)2,16,27 with p < 0.05 and greater than two-fold change. We performed multiple comparative analysis and enrichment analysis on all five stages of liver disease. Functional gene networks were built based on differentially regulated miRNA gene lists as input to generate disease biomarkers and Gene Ontology terms (Data analyzed by Gene Arrays, Entity of Vedic Research, Inc., New York)2,16,27.
Statistical Analysis
Paired student’s t test was used to compare diease stage vs healthy samples, with an FDR < 0.05 considered statistically significant and log2-fold change greater than one. Furthermore, the Benjamini and Hochberg multiple testing adjustment method was applied for all small RNA sequencing studies and an p-value < 0.05 with fold change greater than two for pathway analysis.
Ethics
Data presented in the study was downloaded from the NIH data sets (BioProjects: PRJNA266511 and PRJEB11462). We haven’t recruited any human subjects in this study (Not applicable).
Results
Differential Expression of miRNA in Cirrhosis, LGDN, HGDN, eHCC, and HCC Tissue Samples
We first annotated the datasets to microRNA analysis. Using stringent statistics (FDR < 0.05) with filters set at a log2-fold change greater than one and total minimum reads > 500, expression data was visualized (Fig. 1A–E, Tables 1–5). Our analysis found 87 miRNAs differentially expressed in cirrhosis compared to normal liver tissue (15 upregulated and 72 downregulated; Fig. 1A, Table 1), 106 miRNAs in LGDN (46 upregulated and 60 downregulated; Fig. 1B, Table 2), 59 miRNAs in HGDN (18 upregulated and 41 downregulated; Fig. 1C, Table 3), 80 miRNAs in eHCC (12 upregulated and 68 downregulated; Fig. 1D, Table 4) and 133 miRNAs in HCC (64 upregulated and 69 downregulated; Fig. 1E, Table 5). The top five differentially upregulated miRNAs in cirrhosis (Table 1) were: miR-7704 (403-fold), miR-22 (143-fold), miR-101 (113-fold), miR-486 (75-fold), and miR-192 (32-fold). The top five downregulated were: miR-122 (312-fold), Let-7g (204-fold), miR-103a (83-fold), miR-532 (79-fold), and miR-451a (62-fold). The top five differentially upregulated miRNAs in LGDN (Table 2) were: miR-141 (625-fold), miR-101 (208-fold), miR-22 (111-fold), miR-16 (61-fold), and miR-486 (35-fold); whereas, the top five downregulated were: miR-451a (513-fold), miR-378c (104-fold), miR-361 (95-fold), miR-122 (81-fold), and miR-30c (78-fold). The top five differentially upregulated miRNAs in HGDN (Table 3) were: miR-101 (266-fold), miR-22 (170-fold), miR-16 (54-fold), miR-192 (45-fold), and miR-19b (34-fold). The top five downregulated were: miR-26b (1 million-fold), miR-20a (1 million-fold), Let-7f (1 million-fold), miR-22–3p (1 million-fold), and Let-7c (364-fold). The top five differentially upregulated miRNAs in eHCC (Table 4) were: miR-101 (215-fold), miR-22 (94-fold), miR-10b (34-fold), miR-19b (34-fold), and miR-192 (29-fold). The top five downregulated were: miR-20a (1 million-fold), miR-22–3p (1 million-fold), miR-26b (1 million-fold), Let-7f (1 million-fold), and miR-30c (3545-fold). The top five differentially upregulated miRNAs in HCC (Table 5) were: miR-142 (1 million-fold), miR-7704 (257-fold), miR-101 (147-fold), miR-23a (124-fold), and miR-22 (85-fold); whereas, the top five downregulated were: miR-122 (513-fold), Let-7g (358-fold), miR-378c (187-fold), miR-185 (68-fold), and miR-451a (58-fold).
Table 1.
microRNA ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa-miR-122-5p | 18 | −312.73 | 1.58E-08 |
hsa-let-7g-5p | 3 | −204.40 | 2.12E-04 |
hsa-mir-103a-2 | 20 | −83.22 | 3.85E-04 |
hsa-miR-532-5p | X | −79.93 | 2.96E-04 |
hsa-miR-451a | 17 | −62.96 | 3.56E-04 |
hsa-miR-378c | 10 | −59.31 | 2.52E-04 |
hsa-mir-27b | 9 | −44.44 | 5.86E-04 |
hsa-miR-152-3p | 17 | −44.35 | 6.26E-04 |
hsa-mir-194-2 | 11 | −44.16 | 3.85E-04 |
hsa-miR-185-5p | 22 | −39.71 | 1.44E-03 |
hsa-miR-128-3p | 2 | −31.89 | 2.15E-03 |
hsa-miR-24-3p | 19 | −27.07 | 1.38E-03 |
hsa-let-7a-5p | 11 | −25.41 | 1.22E-04 |
hsa-let-7b-5p | 22 | −23.18 | 6.26E-04 |
hsa-miR-148b-3p | 12 | −21.63 | 9.32E-04 |
hsa-miR-210-3p | 11 | −19.22 | 1.11E-04 |
hsa-mir-23a | 19 | −14.26 | 5.34E-03 |
hsa-miR-139-5p | 11 | −14.07 | 4.82E-03 |
hsa-mir-101-2 | 9 | −13.98 | 2.96E-04 |
hsa-mir-17 | 13 | −13.52 | 6.00E-03 |
hsa-miR-99a-5p | 21 | −12.34 | 1.77E-04 |
hsa-miR-93-5p | 7 | −12.26 | 6.12E-03 |
hsa-mir-199a-2 | 1 | −12.07 | 3.85E-04 |
hsa-miR-125b-5p | 11 | −12.00 | 4.74E-03 |
hsa-mir-3591 | 18 | −11.52 | 2.12E-04 |
hsa-miR-148a-3p | 7 | −10.94 | 2.52E-04 |
hsa-mir-224 | X | −10.83 | 7.73E-03 |
hsa-mir-23b | 9 | −10.81 | 7.29E-03 |
hsa-mir-3607 | 5 | −9.29 | 3.71E-04 |
hsa-miR-450a-5p | X | −7.90 | 1.22E-02 |
hsa-miR-200a-3p | 1 | −7.80 | 1.08E-02 |
hsa-mir-140 | 16 | −7.77 | 1.38E-03 |
hsa-miR-92a-3p | 13 | −7.70 | 1.08E-02 |
hsa-mir-103a-1 | 5 | −7.57 | 1.03E-03 |
hsa-mir-152 | 17 | −7.05 | 1.49E-02 |
hsa-mir-378a | 5 | −6.78 | 2.78E-02 |
hsa-miR-126-3p | 9 | −6.45 | 1.72E-03 |
hsa-miR-574-3p | 4 | −6.41 | 9.98E-03 |
hsa-mir-126 | 9 | −6.26 | 1.55E-02 |
hsa-mir-128-1 | 2 | −5.62 | 2.27E-02 |
hsa-mir-144 | 17 | −5.51 | 9.16E-03 |
hsa-miR-29a-3p | 7 | −5.21 | 5.08E-03 |
hsa-mir-21 | 17 | −4.99 | 3.56E-03 |
hsa-mir-101-1 | 1 | −4.51 | 3.95E-03 |
hsa-let-7e-5p | 19 | −4.45 | 2.27E-02 |
hsa-miR-340-5p | 5 | −4.04 | 9.41E-03 |
hsa-miR-27a-3p | 19 | −3.92 | 6.00E-03 |
hsa-miR-100-5p | 11 | −3.89 | 7.36E-03 |
hsa-miR-26a-5p | 12 | −3.79 | 5.34E-03 |
hsa-mir-199a-1 | 19 | −3.20 | 8.12E-03 |
hsa-miR-215-5p | 1 | −3.07 | 4.17E-02 |
hsa-miR-423-3p | 17 | −3.07 | 1.60E-02 |
hsa-miR-21-5p | 17 | −3.01 | 1.03E-02 |
hsa-miR-30b-5p | 8 | −3.00 | 2.58E-02 |
hsa-mir-106b | 7 | −3.00 | 1.92E-02 |
hsa-mir-125b-2 | 21 | −2.96 | 1.95E-02 |
hsa-mir-455 | 9 | −2.92 | 3.76E-02 |
hsa-mir-195 | 17 | −2.80 | 3.58E-02 |
hsa-mir-26b | 2 | −2.69 | 1.28E-02 |
hsa-miR-107 | 10 | −2.62 | 1.55E-02 |
hsa-mir-3653 | 22 | −2.58 | 4.32E-02 |
hsa-miR-103a-3p | 20 | −2.40 | 1.84E-02 |
hsa-miR-103b | 20 | −2.40 | 1.84E-02 |
hsa-mir-660 | X | −2.34 | 3.88E-02 |
hsa-let-7a-1 | 9 | −2.21 | 3.76E-02 |
hsa-mir-505 | X | −2.21 | 4.32E-02 |
hsa-mir-192 | 11 | −2.03 | 2.27E-02 |
hsa-miR-194-5p | 1 | −1.86 | 2.04E-02 |
hsa-miR-25-3p | 7 | −1.84 | 3.23E-02 |
hsa-let-7i | 12 | −1.65 | 4.73E-02 |
hsa-let-7i-5p | 12 | −1.58 | 4.77E-02 |
hsa-mir-148a | 7 | −1.48 | 2.51E-02 |
hsa-mir-409 | 14 | 7.84 | 4.00E-02 |
hsa-miR-769-5p | 19 | 8.13 | 6.63E-03 |
hsa-miR-320b | 1 | 14.14 | 2.89E-04 |
hsa-mir-136 | 14 | 15.82 | 1.80E-02 |
hsa-miR-127-3p | 14 | 17.15 | 3.85E-04 |
hsa-miR-320a | 8 | 17.51 | 9.02E-06 |
hsa-mir-186 | 1 | 19.52 | 3.85E-04 |
hsa-mir-181c | 19 | 24.73 | 4.46E-02 |
hsa-miR-1307-5p | 10 | 26.74 | 6.00E-03 |
hsa-mir-10b | 2 | 28.57 | 3.03E-02 |
hsa-miR-192-5p | 11 | 31.98 | 1.83E-02 |
hsa-mir-486-2 | 8 | 75.42 | 9.02E-06 |
hsa-miR-101-3p | 1 | 113.21 | 2.51E-02 |
hsa-mir-22 | 17 | 142.96 | 1.05E-07 |
hsa-miR-7704 | 2 | 403.15 | 1.11E-04 |
Table 5.
microRNA ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa-miR-142-5p | 17 | 1000000.00 | 2.06E-11 |
hsa-miR-7704 | 2 | 256.97 | 8.73E-05 |
hsa-miR-101-3p | 1 | 147.24 | 6.28E-08 |
hsa-miR-23a-3p | 19 | 123.92 | 3.72E-08 |
hsa-mir-22 | 17 | 85.32 | 5.45E-17 |
hsa-mir-10b | 2 | 73.25 | 2.02E-10 |
hsa-miR-130b-3p | 22 | 64.54 | 1.41E-06 |
hsa-mir-182 | 7 | 61.30 | 1.51E-02 |
hsa-mir-16-1 | 13 | 57.49 | 2.69E-07 |
hsa-miR-197-3p | 1 | 40.60 | 7.72E-07 |
hsa-miR-192-5p | 11 | 30.83 | 1.59E-10 |
hsa-miR-15a-5p | 13 | 28.71 | 3.39E-05 |
hsa-mir-19b-2 | X | 28.71 | 6.50E-06 |
hsa-mir-486-2 | 8 | 26.10 | 2.41E-08 |
hsa-mir-150 | 19 | 23.61 | 2.20E-03 |
hsa-mir-98 | X | 22.41 | 2.99E-02 |
hsa-miR-199a-3p | 1 | 21.84 | 3.26E-04 |
hsa-mir-181c | 19 | 20.83 | 2.27E-06 |
hsa-mir-183 | 7 | 19.92 | 1.02E-03 |
hsa-mir-181a-1 | 1 | 17.61 | 3.21E-05 |
hsa-miR-182-5p | 7 | 17.27 | 1.32E-03 |
hsa-miR-23b-3p | 9 | 15.46 | 8.41E-06 |
hsa-mir-136 | 14 | 15.45 | 8.72E-06 |
hsa-mir-186 | 1 | 15.42 | 3.23E-10 |
hsa-mir-130a | 11 | 14.61 | 1.33E-03 |
hsa-miR-1307-5p | 10 | 14.53 | 4.71E-03 |
hsa-miR-10b-5p | 2 | 13.00 | 7.50E-07 |
hsa-let-7f-1 | 9 | 12.70 | 5.27E-05 |
hsa-mir-92a-1 | 13 | 10.86 | 3.79E-04 |
hsa-mir-193a | 17 | 10.85 | 3.49E-05 |
hsa-miR-126-5p | 9 | 10.17 | 9.18E-03 |
hsa-mir-191 | 3 | 10.03 | 1.28E-04 |
hsa-mir-26a-1 | 3 | 8.35 | 3.16E-03 |
hsa-mir-181b-1 | 1 | 8.16 | 3.33E-04 |
hsa-miR-30a-5p | 6 | 8.04 | 3.05E-04 |
hsa-mir-30b | 8 | 7.93 | 4.25E-03 |
hsa-mir-10a | 17 | 7.78 | 1.28E-03 |
hsa-mir-29b-2 | 1 | 7.10 | 1.55E-02 |
hsa-miR-204-5p | 9 | 6.73 | 1.89E-03 |
hsa-mir-93 | 7 | 6.48 | 1.29E-03 |
hsa-mir-26a-2 | 12 | 6.36 | 1.10E-02 |
hsa-mir-92a-2 | X | 6.11 | 2.72E-03 |
hsa-miR-127-3p | 14 | 6.02 | 6.97E-05 |
hsa-mir-16-2 | 3 | 6.00 | 9.69E-03 |
hsa-mir-19a | 13 | 5.72 | 4.58E-03 |
hsa-miR-29c-3p | 1 | 5.45 | 1.02E-03 |
hsa-mir-340 | 5 | 5.24 | 4.02E-03 |
hsa-mir-145 | 5 | 5.22 | 2.99E-02 |
hsa-mir-532 | X | 5.15 | 1.77E-03 |
hsa-mir-15b | 3 | 5.13 | 3.17E-02 |
hsa-mir-155 | 21 | 5.10 | 4.11E-03 |
hsa-mir-193b | 16 | 4.87 | 1.51E-05 |
hsa-miR-320a | 8 | 4.43 | 2.20E-03 |
hsa-miR-484 | 16 | 4.20 | 1.95E-02 |
hsa-mir-24-1 | 9 | 4.11 | 3.43E-02 |
hsa-mir-29c | 1 | 3.99 | 3.36E-02 |
hsa-mir-365b | 17 | 3.90 | 1.94E-02 |
hsa-miR-27b-3p | 9 | 3.76 | 3.10E-02 |
hsa-mir-34a | 1 | 3.22 | 1.32E-03 |
hsa-miR-769-5p | 19 | 2.90 | 3.59E-02 |
hsa-mir-100 | 11 | 2.79 | 4.71E-03 |
hsa-mir-125b-1 | 11 | 2.68 | 1.72E-02 |
hsa-miR-221-3p | X | 2.68 | 1.72E-02 |
hsa-mir-409 | 14 | 2.33 | 1.94E-02 |
hsa-miR-146a-5p | 5 | −1.92 | 1.72E-02 |
hsa-let-7i | 12 | −1.95 | 3.26E-02 |
hsa-let-7i-5p | 12 | −1.99 | 1.29E-02 |
hsa-miR-486-5p | 8 | −2.02 | 3.41E-02 |
hsa-mir-106b | 7 | −2.04 | 1.77E-02 |
hsa-miR-378a-3p | 5 | −2.17 | 1.64E-03 |
hsa-let-7e-5p | 19 | −2.21 | 2.28E-02 |
hsa-miR-429 | 1 | −2.26 | 1.60E-02 |
hsa-mir-484 | 16 | −2.27 | 4.71E-02 |
hsa-mir-103a-1 | 5 | −2.36 | 1.72E-02 |
hsa-mir-140 | 16 | −2.41 | 6.53E-03 |
hsa-miR-92a-3p | 13 | −2.43 | 2.22E-02 |
hsa-mir-455 | 9 | −2.46 | 2.18E-02 |
hsa-miR-29a-3p | 7 | −2.50 | 2.40E-02 |
hsa-mir-320a | 8 | −2.69 | 1.73E-03 |
hsa-miR-375 | 2 | −2.75 | 1.34E-02 |
hsa-mir-505 | X | −2.93 | 1.88E-03 |
hsa-mir-99a | 21 | −3.18 | 1.99E-04 |
hsa-miR-215-5p | 1 | −3.25 | 4.40E-04 |
hsa-mir-23b | 9 | −3.28 | 1.83E-02 |
hsa-miR-340-5p | 5 | −3.48 | 1.93E-03 |
hsa-miR-148b-3p | 12 | −3.71 | 4.08E-03 |
hsa-mir-152 | 17 | −3.71 | 6.20E-04 |
hsa-mir-126 | 9 | −3.78 | 3.83E-03 |
hsa-miR-93-5p | 7 | −3.80 | 5.19E-04 |
hsa-mir-125b-2 | 21 | −3.81 | 4.58E-04 |
hsa-mir-17 | 13 | −3.86 | 2.18E-03 |
hsa-miR-423-3p | 17 | −3.90 | 2.13E-04 |
hsa-mir-23a | 19 | −4.19 | 4.31E-02 |
hsa-mir-101-1 | 1 | −4.25 | 8.10E-04 |
hsa-miR-126-3p | 9 | −4.32 | 3.55E-04 |
hsa-mir-3607 | 5 | −4.41 | 5.43E-04 |
hsa-mir-3653 | 22 | −4.48 | 4.14E-06 |
hsa-miR-29b-3p | 1 | −4.55 | 3.10E-02 |
hsa-mir-185 | 22 | −4.72 | 8.54E-05 |
hsa-mir-200b | 1 | −4.78 | 1.02E-03 |
hsa-mir-200a | 1 | −4.85 | 3.16E-03 |
hsa-miR-148a-3p | 7 | −5.38 | 3.59E-05 |
hsa-miR-24-3p | 19 | −5.67 | 1.42E-03 |
hsa-mir-144 | 17 | −5.79 | 2.76E-03 |
hsa-mir-223 | X | −6.03 | 1.37E-02 |
hsa-mir-3591 | 18 | −7.35 | 1.58E-06 |
hsa-miR-139-5p | 11 | −8.35 | 5.27E-05 |
hsa-mir-199a-2 | 1 | −8.74 | 9.79E-03 |
hsa-miR-100-5p | 11 | −8.93 | 3.26E-09 |
hsa-let-7a-5p | 11 | −9.03 | 5.31E-05 |
hsa-miR-128-3p | 2 | −9.93 | 3.52E-05 |
hsa-miR-365b-3p | 17 | −10.55 | 3.70E-03 |
hsa-mir-378a | 5 | −11.05 | 3.72E-08 |
hsa-miR-374a-5p | X | −12.17 | 1.28E-03 |
hsa-mir-194-2 | 11 | −13.00 | 9.17E-06 |
hsa-mir-101-2 | 9 | −13.03 | 5.26E-07 |
hsa-miR-532-5p | X | −14.56 | 9.31E-04 |
hsa-miR-450a-5p | X | −14.85 | 1.26E-06 |
hsa-let-7b-5p | 22 | −15.34 | 1.49E-04 |
hsa-miR-365a-3p | 16 | −16.01 | 1.16E-03 |
hsa-miR-152-3p | 17 | −16.10 | 5.27E-05 |
hsa-miR-200a-3p | 1 | −21.02 | 5.19E-04 |
hsa-mir-27b | 9 | −22.30 | 9.04E-08 |
hsa-mir-424 | X | −23.09 | 1.42E-03 |
hsa-mir-103a-2 | 20 | −23.41 | 1.78E-03 |
hsa-miR-210-3p | 11 | −27.21 | 3.26E-09 |
hsa-miR-99a-5p | 21 | −29.63 | 4.87E-12 |
hsa-miR-125b-5p | 11 | −32.70 | 3.37E-09 |
hsa-miR-451a | 17 | −57.80 | 2.07E-04 |
hsa-miR-185-5p | 22 | −67.83 | 4.08E-11 |
hsa-miR-378c | 10 | −187.61 | 4.37E-07 |
hsa-let-7g-5p | 3 | −358.28 | 1.34E-09 |
hsa-miR-122-5p | 18 | −513.22 | 1.17E-06 |
Table 2.
microRNA ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa-miR-141-3p | 12 | 625.50 | 7.60E-04 |
hsa-miR-101-3p | 1 | 208.06 | 7.45E-06 |
hsa-mir-22 | 17 | 111.76 | 6.50E-10 |
hsa-mir-16-1 | 13 | 60.69 | 1.53E-05 |
hsa-mir-486-2 | 8 | 34.93 | 7.48E-06 |
hsa-miR-192-5p | 11 | 34.41 | 2.10E-06 |
hsa-mir-150 | 19 | 33.64 | 2.15E-04 |
hsa-miR-199a-3p | 1 | 32.48 | 8.85E-04 |
hsa-mir-19b-2 | X | 32.27 | 4.61E-06 |
hsa-miR-15a-5p | 13 | 26.71 | 1.98E-03 |
hsa-mir-10b | 2 | 26.66 | 7.48E-06 |
hsa-mir-181c | 19 | 26.55 | 7.45E-06 |
hsa-mir-181a-1 | 1 | 23.72 | 9.13E-06 |
hsa-mir-130a | 11 | 22.38 | 4.29E-05 |
hsa-miR-424-5p | X | 21.67 | 1.24E-04 |
hsa-let-7f-1 | 9 | 20.45 | 8.44E-05 |
hsa-mir-186 | 1 | 15.49 | 7.48E-06 |
hsa-miR-30a-5p | 6 | 15.34 | 1.37E-03 |
hsa-miR-23b-3p | 9 | 13.80 | 7.60E-04 |
hsa-mir-26a-1 | 3 | 11.20 | 1.99E-03 |
hsa-miR-1307-5p | 10 | 10.97 | 4.06E-02 |
hsa-mir-181b-1 | 1 | 10.53 | 5.98E-05 |
hsa-mir-92a-1 | 13 | 9.89 | 1.51E-04 |
hsa-miR-182-5p | 7 | 9.56 | 2.65E-02 |
hsa-mir-10a | 17 | 9.26 | 2.38E-04 |
hsa-mir-26a-2 | 12 | 8.35 | 8.27E-03 |
hsa-mir-191 | 3 | 8.25 | 2.67E-03 |
hsa-mir-92a-2 | X | 7.75 | 1.55E-03 |
hsa-mir-340 | 5 | 7.19 | 2.26E-03 |
hsa-miR-126-5p | 9 | 6.67 | 6.16E-03 |
hsa-miR-29c-3p | 1 | 6.49 | 9.39E-04 |
hsa-mir-16-2 | 3 | 6.39 | 3.99E-02 |
hsa-miR-127-3p | 14 | 6.04 | 3.77E-03 |
hsa-mir-19a | 13 | 5.91 | 2.26E-03 |
hsa-mir-30b | 8 | 5.51 | 1.27E-02 |
hsa-mir-155 | 21 | 5.47 | 1.70E-02 |
hsa-mir-100 | 11 | 5.34 | 5.61E-04 |
hsa-miR-10b-5p | 2 | 5.12 | 4.41E-03 |
hsa-mir-145 | 5 | 4.71 | 8.60E-03 |
hsa-let-7d | 9 | 4.66 | 2.23E-02 |
hsa-miR-320a | 8 | 4.27 | 2.86E-03 |
hsa-mir-181b-2 | 9 | 3.70 | 1.65E-02 |
hsa-mir-532 | X | 3.63 | 4.22E-02 |
hsa-mir-125b-1 | 11 | 3.18 | 1.70E-02 |
hsa-mir-34a | 1 | 2.94 | 4.06E-02 |
hsa-mir-193b | 16 | 2.45 | 4.20E-02 |
hsa-miR-200a-3p | 1 | −1.78 | 4.37E-02 |
hsa-let-7i-5p | 12 | −1.78 | 4.66E-02 |
hsa-miR-215-5p | 1 | −1.96 | 3.38E-02 |
hsa-mir-455 | 9 | −2.03 | 4.12E-02 |
hsa-mir-21 | 17 | −2.08 | 2.65E-02 |
hsa-let-7e-5p | 19 | −2.10 | 3.33E-02 |
hsa-mir-3120 | 1 | −2.20 | 3.66E-02 |
hsa-miR-92a-3p | 13 | −2.21 | 1.74E-02 |
hsa-mir-101-1 | 1 | −2.22 | 3.72E-02 |
hsa-mir-99a | 21 | −2.28 | 1.74E-02 |
hsa-mir-103a-1 | 5 | −2.29 | 2.11E-02 |
hsa-mir-224 | X | −2.34 | 3.22E-02 |
hsa-mir-106b | 7 | −2.34 | 1.61E-02 |
hsa-mir-140 | 16 | −3.01 | 6.10E-03 |
hsa-mir-320a | 8 | −3.02 | 3.79E-03 |
hsa-mir-23b | 9 | −3.12 | 7.86E-03 |
hsa-mir-144 | 17 | −3.19 | 4.12E-02 |
hsa-mir-152 | 17 | −3.28 | 2.51E-03 |
hsa-mir-125b-2 | 21 | −3.47 | 4.41E-03 |
hsa-miR-340-5p | 5 | −3.52 | 2.16E-03 |
hsa-miR-148a-3p | 7 | −4.16 | 3.07E-03 |
hsa-miR-148b-3p | 12 | −4.20 | 6.24E-03 |
hsa-mir-17 | 13 | −4.21 | 1.70E-03 |
hsa-miR-423-3p | 17 | −4.43 | 4.41E-03 |
hsa-mir-3607 | 5 | −4.44 | 1.60E-03 |
hsa-miR-93-5p | 7 | −4.74 | 7.05E-04 |
hsa-mir-126 | 9 | −4.75 | 5.55E-04 |
hsa-mir-3653 | 22 | −4.81 | 1.33E-04 |
hsa-miR-126-3p | 9 | −4.89 | 2.43E-04 |
hsa-mir-23a | 19 | −5.30 | 1.44E-03 |
hsa-miR-24-3p | 19 | −5.44 | 2.26E-03 |
hsa-let-7a-5p | 11 | −5.53 | 7.60E-04 |
hsa-miR-139-5p | 11 | −5.53 | 3.98E-04 |
hsa-mir-3591 | 18 | −6.30 | 2.41E-04 |
hsa-mir-199a-2 | 1 | −6.72 | 1.77E-04 |
hsa-let-7b-5p | 22 | −6.81 | 8.14E-04 |
hsa-mir-101-2 | 9 | −6.99 | 2.88E-04 |
hsa-mir-378a | 5 | −7.06 | 5.82E-05 |
hsa-miR-100-5p | 11 | −7.71 | 1.06E-05 |
hsa-miR-128-3p | 2 | −8.01 | 5.61E-04 |
hsa-mir-194-2 | 11 | −8.52 | 3.03E-04 |
hsa-let-7d-5p | 9 | −10.76 | 9.51E-03 |
hsa-miR-450a-5p | X | −12.31 | 2.38E-05 |
hsa-miR-210-3p | 11 | −12.69 | 1.77E-05 |
hsa-miR-152-3p | 17 | −14.35 | 2.06E-05 |
hsa-miR-532-5p | X | −15.17 | 3.77E-03 |
hsa-mir-424 | X | −15.74 | 1.47E-05 |
hsa-mir-27b | 9 | −17.77 | 7.48E-06 |
hsa-let-7c-5p | 21 | −19.23 | 1.62E-03 |
hsa-miR-125b-5p | 11 | −20.94 | 1.17E-05 |
hsa-miR-99a-5p | 21 | −27.01 | 4.07E-08 |
hsa-mir-103a-2 | 20 | −28.04 | 4.82E-06 |
hsa-miR-185-5p | 22 | −68.06 | 2.60E-08 |
hsa-miR-374a-5p | X | −69.55 | 4.61E-06 |
hsa-let-7g-5p | 3 | −77.05 | 4.07E-08 |
hsa-miR-30c-5p | 1 | −77.77 | 1.33E-04 |
hsa-miR-122-5p | 18 | −80.83 | 4.82E-06 |
hsa-miR-361-3p | X | −94.56 | 3.30E-05 |
hsa-miR-378c | 10 | −103.67 | 5.71E-05 |
hsa-miR-451a | 17 | −513.04 | 2.05E-06 |
Table 3.
microRNA ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa-miR-101-3p | 1 | 266.25 | 1.10E-02 |
hsa-mir-22 | 17 | 169.91 | 1.30E-10 |
hsa-mir-16-1 | 13 | 53.70 | 5.87E-03 |
hsa-miR-192-5p | 11 | 45.02 | 1.43E-04 |
hsa-mir-19b-2 | X | 34.12 | 1.68E-03 |
hsa-mir-486-2 | 8 | 25.83 | 1.76E-04 |
hsa-mir-130a | 11 | 24.80 | 4.06E-02 |
hsa-mir-186 | 1 | 23.55 | 2.97E-06 |
hsa-miR-424-5p | X | 20.63 | 1.50E-02 |
hsa-mir-10b | 2 | 16.15 | 1.11E-02 |
hsa-mir-181a-1 | 1 | 16.09 | 4.85E-04 |
hsa-miR-320a | 8 | 13.48 | 2.01E-02 |
hsa-mir-10a | 17 | 8.93 | 2.30E-02 |
hsa-mir-191 | 3 | 8.80 | 2.81E-02 |
hsa-mir-92a-1 | 13 | 8.19 | 1.46E-02 |
hsa-miR-127-3p | 14 | 4.94 | 8.02E-03 |
hsa-mir-193b | 16 | 4.90 | 1.09E-02 |
hsa-mir-100 | 11 | 4.11 | 3.72E-03 |
hsa-mir-125b-2 | 21 | −2.90 | 4.18E-02 |
hsa-mir-106b | 7 | −3.01 | 4.27E-02 |
hsa-miR-99b-5p | 19 | −3.02 | 2.47E-02 |
hsa-mir-200b | 1 | −3.81 | 2.62E-02 |
hsa-mir-140 | 16 | −3.91 | 1.53E-02 |
hsa-miR-148b-3p | 12 | −3.99 | 2.34E-02 |
hsa-miR-126-3p | 9 | −4.34 | 1.67E-02 |
hsa-mir-3591 | 18 | −4.43 | 1.09E-02 |
hsa-miR-100-5p | 11 | −4.74 | 1.48E-03 |
hsa-mir-3607 | 5 | −5.39 | 1.35E-02 |
hsa-miR-423-3p | 17 | −6.19 | 3.76E-03 |
hsa-mir-101-2 | 9 | −6.49 | 1.53E-02 |
hsa-miR-93-5p | 7 | −6.63 | 2.12E-03 |
hsa-let-7a-5p | 11 | −6.99 | 1.31E-02 |
hsa-miR-24-3p | 19 | −7.33 | 5.92E-03 |
hsa-mir-199a-2 | 1 | −7.90 | 1.40E-03 |
hsa-miR-450a-5p | X | −10.52 | 3.21E-02 |
hsa-miR-374a-5p | X | −13.20 | 1.31E-02 |
hsa-miR-99a-5p | 21 | −13.46 | 2.70E-05 |
hsa-mir-27b | 9 | −14.75 | 4.93E-04 |
hsa-miR-152-3p | 17 | −14.77 | 1.82E-02 |
hsa-miR-125b-5p | 11 | −15.62 | 6.66E-03 |
hsa-miR-128-3p | 2 | −16.39 | 2.13E-02 |
hsa-miR-210-3p | 11 | −16.54 | 1.43E-04 |
hsa-mir-424 | X | −21.44 | 1.78E-02 |
hsa-let-7b-5p | 22 | −21.90 | 1.81E-02 |
hsa-miR-200a-3p | 1 | −24.56 | 1.34E-02 |
hsa-miR-532-5p | X | −27.50 | 1.64E-04 |
hsa-mir-103a-2 | 20 | −30.41 | 1.35E-02 |
hsa-miR-451a | 17 | −35.59 | 1.48E-03 |
hsa-let-7d-5p | 9 | −35.82 | 5.12E-03 |
hsa-miR-185-5p | 22 | −70.25 | 3.66E-07 |
hsa-miR-378c | 10 | −76.83 | 2.87E-05 |
hsa-let-7g-5p | 3 | −237.19 | 1.48E-03 |
hsa-miR-122-5p | 18 | −243.58 | 4.71E-07 |
hsa-miR-30c-5p | 1 | −298.01 | 1.10E-04 |
hsa-let-7c-5p | 21 | −364.58 | 3.61E-05 |
hsa-miR-22-3p | 17 | −1000000.00 | 1.03E-16 |
hsa-let-7f-5p | 9 | −1000000.00 | 1.03E-16 |
hsa-miR-26b-5p | 2 | −1000000.00 | 1.95E-16 |
hsa-miR-20a-5p | 13 | −1000000.00 | 3.67E-16 |
Table 4.
microRNA ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa-miR-101-3p | 1 | 215.60 | 4.49E-03 |
hsa-mir-22 | 17 | 94.20 | 9.45E-09 |
hsa-mir-10b | 2 | 34.24 | 9.28E-04 |
hsa-mir-19b-2 | X | 29.45 | 9.73E-03 |
hsa-miR-192-5p | 11 | 29.09 | 1.14E-03 |
hsa-mir-486-2 | 8 | 26.76 | 7.29E-04 |
hsa-miR-320a | 8 | 18.04 | 9.73E-03 |
hsa-mir-186 | 1 | 16.42 | 6.95E-05 |
hsa-miR-127-3p | 14 | 15.94 | 1.09E-02 |
hsa-mir-181a-1 | 1 | 9.96 | 2.97E-03 |
hsa-mir-193b | 16 | 3.63 | 1.84E-02 |
hsa-mir-100 | 11 | 3.29 | 1.06E-02 |
hsa-mir-21 | 17 | −2.07 | 3.11E-02 |
hsa-miR-92a-3p | 13 | −2.20 | 1.53E-02 |
hsa-let-7i-5p | 12 | −2.39 | 1.84E-02 |
hsa-miR-99b-5p | 19 | −2.48 | 1.84E-02 |
hsa-mir-455 | 9 | −2.60 | 2.48E-02 |
hsa-mir-99a | 21 | −2.70 | 1.60E-02 |
hsa-mir-200b | 1 | −2.76 | 2.49E-02 |
hsa-mir-3653 | 22 | −2.77 | 1.72E-02 |
hsa-let-7i | 12 | −2.78 | 1.84E-02 |
hsa-mir-200a | 1 | −2.80 | 3.77E-02 |
hsa-miR-29a-3p | 7 | −2.87 | 1.84E-02 |
hsa-miR-215-5p | 1 | −2.89 | 1.77E-02 |
hsa-mir-101-1 | 1 | −2.97 | 1.63E-02 |
hsa-let-7e-5p | 19 | −3.05 | 1.59E-02 |
hsa-miR-27a-3p | 19 | −3.47 | 1.44E-02 |
hsa-mir-106b | 7 | −3.60 | 7.83E-03 |
hsa-mir-128-1 | 2 | −3.63 | 2.07E-02 |
hsa-miR-340-5p | 5 | −3.87 | 8.94E-03 |
hsa-miR-150-5p | 19 | −3.90 | 1.06E-02 |
hsa-mir-199a-1 | 19 | −4.02 | 9.64E-03 |
hsa-miR-148b-3p | 12 | −4.14 | 5.46E-03 |
hsa-mir-23b | 9 | −4.38 | 9.73E-03 |
hsa-miR-148a-3p | 7 | −4.55 | 8.26E-03 |
hsa-mir-125b-2 | 21 | −4.84 | 5.35E-03 |
hsa-mir-103a-1 | 5 | −5.16 | 5.75E-03 |
hsa-mir-17 | 13 | −5.22 | 6.28E-03 |
hsa-mir-152 | 17 | −5.92 | 2.77E-03 |
hsa-mir-3607 | 5 | −6.14 | 3.00E-03 |
hsa-miR-100-5p | 11 | −6.19 | 4.14E-04 |
hsa-mir-126 | 9 | −7.00 | 2.19E-03 |
hsa-let-7a-5p | 11 | −7.06 | 2.77E-03 |
hsa-mir-140 | 16 | −7.07 | 2.31E-03 |
hsa-miR-126-3p | 9 | −7.18 | 1.73E-03 |
hsa-mir-23a | 19 | −8.07 | 1.47E-03 |
hsa-miR-93-5p | 7 | −8.58 | 8.01E-04 |
hsa-mir-3591 | 18 | −8.87 | 7.27E-04 |
hsa-mir-101-2 | 9 | −9.79 | 2.08E-03 |
hsa-miR-450a-5p | X | −10.96 | 7.29E-04 |
hsa-miR-24-3p | 19 | −11.91 | 2.08E-03 |
hsa-mir-144 | 17 | −12.34 | 4.51E-03 |
hsa-mir-194-2 | 11 | −12.62 | 1.84E-03 |
hsa-miR-200a-3p | 1 | −12.71 | 1.39E-02 |
hsa-miR-139-5p | 11 | −13.55 | 1.18E-02 |
hsa-miR-210-3p | 11 | −13.69 | 8.98E-05 |
hsa-mir-199a-2 | 1 | −14.20 | 3.57E-04 |
hsa-miR-128-3p | 2 | −18.16 | 7.74E-03 |
hsa-miR-152-3p | 17 | −18.61 | 3.51E-03 |
hsa-miR-374a-5p | X | −19.82 | 1.14E-03 |
hsa-miR-99a-5p | 21 | −20.45 | 5.10E-06 |
hsa-let-7b-5p | 22 | −21.06 | 9.64E-03 |
hsa-miR-125b-5p | 11 | −24.27 | 1.78E-04 |
hsa-miR-532-5p | X | −27.40 | 5.35E-03 |
hsa-let-7d-5p | 9 | −32.21 | 3.51E-03 |
hsa-mir-27b | 9 | −32.67 | 1.05E-04 |
hsa-mir-424 | X | −46.39 | 3.61E-03 |
hsa-mir-103a-2 | 20 | −51.50 | 4.95E-06 |
hsa-miR-185-5p | 22 | −58.42 | 4.53E-06 |
hsa-let-7c-5p | 21 | −68.82 | 2.19E-03 |
hsa-miR-378c | 10 | −82.90 | 6.70E-07 |
hsa-miR-451a | 17 | −188.05 | 4.57E-04 |
hsa-miR-122-5p | 18 | −236.49 | 5.10E-06 |
hsa-let-7g-5p | 3 | −405.25 | 9.45E-09 |
hsa-miR-361-3p | X | −2902.32 | 6.70E-07 |
hsa-miR-30c-5p | 1 | −3544.83 | 2.77E-06 |
hsa-let-7f-5p | 9 | −1000000.00 | 5.42E-17 |
hsa-miR-22-3p | 17 | −1000000.00 | 5.42E-17 |
hsa-miR-26b-5p | 2 | −1000000.00 | 3.58E-16 |
hsa-miR-20a-5p | 13 | −1000000.00 | 4.76E-16 |
Broadly visualized data for all five groups was represented in a Venn diagram (Fig. 1F), which showed 37 miRs are commonly expressed in all groups whereas, 16 miRs in cirrhosis, four miRs in LGDN, none in HGDN, one miR in eHCC, and 29 miRs in HCC are uniquely expressed (Fig. 1F). Several miRs expression patterns were common between groups, specifically 24 miRs in LGDN and HCC and 18 miRs in cirrhosis, LGDN, eHCC, and HCC (Fig. 1F). Circos Plots were prepared for comprehensive visualization of differentially expressed miRs in all five groups, including chromosome number and location (Fig. 1G). Black lines inside respective rings show the affected gene location and chromosome number. After plugging the data into Circos Plot, we found chromosomes 1, 2, 9, 13, and 17 were the most enriched chromosomes in all five groups (Fig. 1G).
Validation of Differentially Expressed miRNAs in HCC Clinical Samples
In order to validate in silico miRNA sequencing data from a publically available source, we used human HCC specimens compared to healthy liver tissues by using an absolute quantification miRNA assay from NanoString technologies, which screens for more than 800 human miRNAs, validated to an independent cohort of tissue samples. In our analysis, we found more than 274 miRNAs were differentially expressed by more than a two fold change compared to healthy liver samples. We then exported the data using fold change (up and down regulated miRNAs) and compared miRNA-seq differentially expressed miRNAs in the HCC group using FunRich software. We created a grouped heatmap for the top 20 upregulated and downregulated miRNAs (Fig. 1I) and compared differentially expressed genes between the miRNA-seq and NanoString miRNA assays (Fig. 1H). We identified 21 miRNAs using a Venn diagram with 11 of them showing similar trends as the sequenced data (Table 6). Five miRNAs were upregulated (miR-130b, miR-182, miR10b, miR320a, and miR769) ranging from a 2.9 to 30-fold induction in the NanoString miRNA assay, whereas six miRNAs were downregulated (miR122, miR451a, miR200a, miR139, miR148a, and miR375) ranging from −2.2 to −6 fold (Table 6).
Table 6.
HCC miRNA-seq | HCC Nanostring data-2FC | ||
---|---|---|---|
microRNA ID | Fold change | miRNA | Fold Change |
hsa-miR-130b-3p | 64.54 | hsa-miR-130b-3p | 30.06 |
hsa-miR-182-5p | 17.27 | hsa-miR-182-5p | 3.97 |
hsa-miR-10b-5p | 13.00 | hsa-miR-10b-5p | 4.08 |
hsa-miR-320a | 4.43 | hsa-miR-320a | 8.68 |
hsa-miR-769-5p | 2.90 | hsa-miR-769-5p | 2.91 |
hsa-miR-375 | −2.75 | hsa-miR-375 | −4.54 |
hsa-miR-148a-3p | −5.38 | hsa-miR-148a-3p | −2.28 |
hsa-miR-139-5p | −8.35 | hsa-miR-139-5p | −6.01 |
hsa-miR-200a-3p | −21.02 | hsa-miR-200a-3p | −5.43 |
hsa-miR-451a | −57.80 | hsa-miR-451a | −3.49 |
hsa-miR-122-5p | −513.22 | hsa-miR-122-5p | −3.31 |
Following miRNA expression analysis, we used MetaCore pathway software to analyze the possible signaling pathways affected and enriched microRNAs role in cirrhosis and HCC pathogenesis. We uploaded all the differentially expressed miRNAs to the MetaCore server for comparative and gene enrichment analysis (Figs 2, 3 and 4). Processed data for comparative enrichment analysis showed a three way representation (common-high significance in all groups, similar-similarly enriched in all groups, and unique-various pathways specifically expressed in the individual groups). We found 112 pathways to be common, 177 similar, and a number unique to each group. 49 pathways were unique to advanced HCC data sets (Fig. 2A). Pathway Maps were utilized for comparative and enrichment analysis of differentially expressed miRNAs for biological pathways analysis (The results were obtained using MetaCore pathways analysis tool; GeneGo/Thomson Reuters). Diseased samples clearly showed involvement of signaling molecules in microRNA dependent EMT, CD44 signaling, and others (Fig. 2B). Gene Ontology (GO) Processes analysis revealed that most affected miRNAs were involved in the cellular response to amino acid and chemical stimulus, with HCC being the most affected group (Fig. 3A). Many cancer-related categories were over-represented via Disease Stages by Biomarkers analysis (Fig. 3B). Disease Stages by Biomarkers analysis found the most affected miRNAs were involved in cancer signaling pathways including renal, non-small cell lung, bronchogenic, and hepatocellular cancers (Fig. 3A). Biological network analysis of miRNAs involved in the highest affected network processes are listed in Fig. 4A with the top three commonly regulated networks in all five groups (Fig. 4A), top three similarly affected networks (Fig. 4B), and top uniquely regulated biological network pathways in liver disease shown in Fig. 4C–F.
Differential Expression of piRNA in Cirrhosis, LGDN, HGDN, eHCC, and HCC Tissue Samples
piRNAs are the largest class of endogenous non-coding RNAs. They have recently been shown to play important biological roles as RNA silencers; forming RNA-protein complexes that are required for both epigenetic and post-transcriptional gene silencing in germ line cells2,28. We used piRNA annotation to identify piRNA differential expression in cirrhosis, LGDN, HGDN, eHCC, and HCC groups (Fig. 5A–E, Tables 6–10). We found 75 piRNAs associated with cirrhosis (16 upregulated and 59 downregulated; Fig. 5A, Table 7), 60 piRNAs in LGDN (28 upregulated and 32 downregulated; Fig. 5B, Table 8), 49 piRNAs in HGDN (12 upregulated and 37 downregulated; Fig. 5C, Table 9), 56 piRNAs in eHCC (9 upregulated and 46 downregulated; Fig. 5D, Table 10), and 128 piRNAs in HCC (83 upregulated and 45 downregulated; Fig. 5E, Table 11). The top five differentially upregulated piRNAs in cirrhosis (Table 7) were: piR-32299 (7658-fold), piR-28488 (2105-fold), piR-7239 (1497-fold), piR-5939 (536-fold), and piR-5067 (106-fold); whereas, the top five downregulated were: piR-952 (423-fold), piR-28525 (140-fold), piR-5938 (87-fold), piR-5937 (65-fold), and piR-25780 (49-fold). The top five differentially upregulated piRNAs in LGDN (Table 8) were: piR-32299 (5557-fold), piR-28488 (1804-fold), piR-7239 (1139-fold), piR-5939 (627-fold), and piR-23655 (90-fold). The top five downregulated were: piR-952 (450-fold), piR-12759 (270-fold), piR-820 (101-fold), piR-28525 (82-fold), and piR-5937 (37-fold). The top five differentially upregulated piRNAs in HGDN (Table 9) were: piR-28488 (1013-fold), piR-7239 (798-fold), piR-5939 (281-fold), piR-23655 (96-fold), and piR-6147 (26-fold); with downregulation of: piR-12759 (534-fold), piR-952 (469-fold), piR-25782 (309-fold, top 10, out of 6 were alternative number transcripts of this gene with fold change ranging 94–309), piR-820 (130-fold), and piR-28525 (116-fold). The top five differentially upregulated piRNAs in eHCC (Table 10) were: piR-28488 (1966-fold), piR-7239 (1629-fold), piR-5939 (718-fold), piR-1338 (56-fold), and piR-23786 (18-fold); whereas, the top five downregulated were: piR-952 (383-fold), piR-5937 (121-fold), piR-5938 (108-fold), piR-820 (99-fold), and piR-28525 (81-fold). The top five differentially upregulated piRNAs in HCC (Table 11) were: piR-32299 (4045-fold), piR-23670 (2335-fold), piR-24684 (2220-fold), piR-28488 (1099-fold), and piR-7239 (949-fold). On the other hand, piR-952 (518-fold), piR-820 (78-fold), piR-28525 (58-fold), piR-5938 (57-fold), and piR-5937 (52-fold) were downregulated. Further investigation is needed to evaluate their functions in diseased states, as there is very limited literature available on their functionality.
Table 10.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
piR-hsa-28488 | 6 | 1966.20 | 2.53E-07 |
piR-hsa-7239 | 2 | 1629.10 | 1.08E-06 |
piR-hsa-5939 | 12 | 718.32 | 1.08E-06 |
piR-hsa-1338 | 11 | 55.63 | 4.90E-05 |
piR-hsa-23786 | 20 | 18.06 | 7.48E-05 |
piR-hsa-3178 | 20 | 12.31 | 1.78E-03 |
piR-hsa-1823 | 2 | 8.23 | 2.73E-03 |
piR-hsa-27616 | 19 | 5.29 | 9.09E-03 |
piR-hsa-14647 | 9 | 4.66 | 8.69E-03 |
piR-hsa-793 | Y | −1.62 | 4.58E-02 |
piR-hsa-11362 | 21 | −1.94 | 2.81E-02 |
piR-hsa-26686 | M | −2.15 | 2.02E-02 |
piR-hsa-26685 | M | −2.43 | 1.24E-02 |
piR-hsa-993 | 5 | −2.46 | 1.95E-02 |
piR-hsa-11361 | 9 | −2.53 | 8.71E-03 |
piR-hsa-9010 | 17 | −2.95 | 8.69E-03 |
piR-hsa-23317 | 6 | −3.13 | 1.65E-02 |
piR-hsa-26039 | 17 | −3.58 | 4.48E-03 |
piR-hsa-11360 | 9 | −3.70 | 6.03E-03 |
piR-hsa-26508.6 | X | −4.56 | 6.03E-03 |
piR-hsa-24672.1 | 1 | −4.59 | 2.73E-03 |
piR-hsa-24672 | 1 | −4.60 | 2.83E-03 |
piR-hsa-27282 | 14 | −4.69 | 9.52E-04 |
piR-hsa-24672.3 | 6 | −4.71 | 2.73E-03 |
piR-hsa-28131.3 | 3 | −4.74 | 2.33E-02 |
piR-hsa-1207.2 | 16 | −4.76 | 2.33E-02 |
piR-hsa-1207.1 | 16 | −4.78 | 2.33E-02 |
piR-hsa-28131.1 | 1 | −4.79 | 2.33E-02 |
piR-hsa-1207.3 | 16 | −4.79 | 2.26E-02 |
piR-hsa-24672.4 | 6 | −4.80 | 2.67E-03 |
piR-hsa-28131 | 1 | −4.84 | 2.23E-02 |
piR-hsa-2117 | 7 | −4.85 | 1.28E-03 |
piR-hsa-28131.4 | 6 | −4.87 | 2.26E-02 |
piR-hsa-1207.4 | 2 | −4.87 | 2.26E-02 |
piR-hsa-1207.5 | 5 | −4.87 | 2.21E-02 |
piR-hsa-1207 | 1 | −4.88 | 2.26E-02 |
piR-hsa-28131.2 | 16 | −4.90 | 2.24E-02 |
piR-hsa-26684 | M | −4.99 | 1.89E-03 |
piR-hsa-26681 | M | −4.99 | 1.89E-03 |
piR-hsa-27493 | 1 | −5.54 | 6.01E-03 |
piR-hsa-2153 | 11 | −5.95 | 2.47E-02 |
piR-hsa-25780.10 | 4 | −8.01 | 1.83E-02 |
piR-hsa-1177 | 19 | −9.36 | 1.92E-04 |
piR-hsa-28478 | 2 | −10.27 | 3.44E-05 |
piR-hsa-3200 | 16 | −13.35 | 7.06E-04 |
piR-hsa-20757.2 | 1 | −13.91 | 6.03E-03 |
piR-hsa-963 | 17 | −16.72 | 6.03E-03 |
piR-hsa-20613 | 7 | −20.96 | 3.11E-03 |
piR-hsa-25780.9 | 3 | −24.55 | 1.08E-02 |
piR-hsa-25780 | 1 | −24.99 | 1.14E-02 |
piR-hsa-25780.1 | 1 | −26.09 | 8.69E-03 |
piR-hsa-28525 | 4 | −81.22 | 1.51E-03 |
piR-hsa-820 | 2 | −99.09 | 4.65E-04 |
piR-hsa-5938 | 3 | −108.31 | 2.58E-06 |
piR-hsa-5937 | 3 | −120.72 | 2.53E-07 |
piR-hsa-952 | 22 | −382.71 | 1.07E-09 |
Table 7.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
piR-hsa-32299 | 1 | 7658.01 | 3.35E-08 |
piR-hsa-28488 | 6 | 2105.61 | 5.75E-13 |
piR-hsa-7239 | 2 | 1496.87 | 8.21E-12 |
piR-hsa-5939 | 12 | 535.89 | 6.35E-11 |
piR-hsa-5067.1 | 3 | 106.36 | 3.35E-08 |
piR-hsa-5067.4 | 6 | 101.29 | 2.01E-05 |
piR-hsa-1338 | 11 | 59.72 | 5.59E-10 |
piR-hsa-26754 | 5 | 27.08 | 1.68E-05 |
piR-hsa-23786 | 20 | 24.42 | 5.04E-05 |
piR-hsa-28487 | 2 | 16.72 | 4.06E-05 |
piR-hsa-3178 | 20 | 14.72 | 3.97E-06 |
piR-hsa-1823 | 2 | 10.13 | 4.39E-04 |
piR-hsa-14647 | 9 | 5.50 | 1.90E-02 |
piR-hsa-27616 | 19 | 4.59 | 1.11E-03 |
piR-hsa-28319 | 9 | 2.84 | 2.34E-02 |
piR-hsa-28319.1 | 9 | 2.75 | 4.02E-02 |
piR-hsa-27283 | 20 | −1.61 | 4.30E-02 |
piR-hsa-28875 | 2 | −1.76 | 3.05E-02 |
piR-hsa-28875.1 | M | −1.81 | 2.88E-02 |
piR-hsa-17444 | 20 | −2.00 | 1.13E-02 |
piR-hsa-1191 | 17 | −2.00 | 1.81E-02 |
piR-hsa-993 | 5 | −2.05 | 2.57E-02 |
piR-hsa-11362 | 21 | −2.22 | 1.14E-02 |
piR-hsa-20266 | 5 | −2.43 | 2.20E-02 |
piR-hsa-20266.1 | M | −2.47 | 1.80E-02 |
piR-hsa-29218 | 7 | −2.49 | 2.58E-02 |
piR-hsa-26039 | 17 | −2.56 | 1.06E-02 |
piR-hsa-24672 | 1 | −2.88 | 8.53E-03 |
piR-hsa-24672.3 | 6 | −2.89 | 9.35E-03 |
piR-hsa-24672.4 | 6 | −2.92 | 8.53E-03 |
piR-hsa-24672.1 | 1 | −2.94 | 8.53E-03 |
piR-hsa-26686 | M | −3.29 | 4.19E-03 |
piR-hsa-1207.3 | 16 | −3.73 | 1.14E-02 |
piR-hsa-28131.3 | 3 | −3.76 | 1.29E-02 |
piR-hsa-28131.1 | 1 | −3.76 | 1.14E-02 |
piR-hsa-1207.1 | 16 | −3.76 | 1.14E-02 |
piR-hsa-28131 | 1 | −3.76 | 1.29E-02 |
piR-hsa-1207.2 | 16 | −3.76 | 1.15E-02 |
piR-hsa-28131.2 | 16 | −3.79 | 1.17E-02 |
piR-hsa-1207.4 | 2 | −3.80 | 1.14E-02 |
piR-hsa-1207 | 1 | −3.81 | 1.15E-02 |
piR-hsa-1207.5 | 5 | −3.82 | 1.14E-02 |
piR-hsa-28131.4 | 6 | −3.86 | 1.14E-02 |
piR-hsa-28877 | 5 | −4.01 | 1.65E-02 |
piR-hsa-25447 | 18 | −4.34 | 1.61E-02 |
piR-hsa-26685 | M | −4.57 | 1.13E-03 |
piR-hsa-2117 | 7 | −4.72 | 5.57E-05 |
piR-hsa-793 | Y | −6.89 | 1.09E-04 |
piR-hsa-23317 | 6 | −7.42 | 5.59E-04 |
piR-hsa-26681 | M | −7.51 | 2.61E-05 |
piR-hsa-26684 | M | −7.51 | 2.61E-05 |
piR-hsa-25780.10 | 4 | −8.41 | 8.46E-03 |
piR-hsa-27282 | 14 | −9.65 | 3.76E-07 |
piR-hsa-28478 | 2 | −9.94 | 7.01E-07 |
piR-hsa-12789 | Y | −10.01 | 1.38E-05 |
piR-hsa-20757.2 | 1 | −10.06 | 9.74E-03 |
piR-hsa-2153 | 11 | −10.23 | 2.96E-03 |
piR-hsa-27731 | 7 | −10.91 | 5.62E-03 |
piR-hsa-27731.1 | M | −11.09 | 4.53E-03 |
piR-hsa-11360 | 9 | −11.75 | 1.20E-04 |
piR-hsa-20613 | 7 | −12.07 | 8.94E-06 |
piR-hsa-9010 | 17 | −12.43 | 3.80E-06 |
piR-hsa-26508.6 | X | −12.64 | 2.39E-03 |
piR-hsa-11361 | 9 | −12.75 | 1.29E-04 |
piR-hsa-3200 | 16 | −12.86 | 1.95E-03 |
piR-hsa-27493 | 1 | −14.50 | 2.96E-03 |
piR-hsa-1177 | 19 | −18.54 | 3.42E-08 |
piR-hsa-963 | 17 | −20.24 | 9.10E-04 |
piR-hsa-25780.1 | 1 | −47.39 | 1.05E-03 |
piR-hsa-25780 | 1 | −47.84 | 1.47E-03 |
piR-hsa-25780.9 | 3 | −48.83 | 1.06E-03 |
piR-hsa-5937 | 3 | −64.99 | 3.60E-07 |
piR-hsa-5938 | 3 | −86.53 | 6.29E-07 |
piR-hsa-28525 | 4 | −139.56 | 6.96E-05 |
piR-hsa-952 | 22 | −424.84 | 1.07E-05 |
Table 8.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
piR-hsa-32299 | 1 | 5556.66 | 6.74E-06 |
piR-hsa-28488 | 6 | 1804.05 | 1.10E-09 |
piR-hsa-7239 | 2 | 1138.69 | 7.04E-09 |
piR-hsa-5939 | 12 | 626.82 | 1.10E-09 |
piR-hsa-23655 | 5 | 100.84 | 8.37E-06 |
piR-hsa-12488 | 11 | 31.18 | 8.05E-06 |
piR-hsa-6147 | 2 | 29.33 | 1.29E-03 |
piR-hsa-12488.1 | M | 27.82 | 8.56E-06 |
piR-hsa-1338 | 11 | 17.68 | 2.04E-08 |
piR-hsa-23786 | 20 | 13.72 | 1.96E-07 |
piR-hsa-26131 | 7 | 10.87 | 2.05E-02 |
piR-hsa-15023.1 | M | 7.25 | 2.11E-02 |
piR-hsa-15023 | 8 | 6.80 | 3.64E-02 |
piR-hsa-28190 | 11 | 6.77 | 8.81E-04 |
piR-hsa-3178 | 20 | 6.45 | 4.65E-03 |
piR-hsa-25783.4 | 16 | 5.91 | 4.11E-03 |
piR-hsa-27616 | 19 | 5.75 | 2.05E-04 |
piR-hsa-25783.8 | 6 | 5.71 | 4.65E-03 |
piR-hsa-25783.1 | 16 | 5.63 | 5.28E-03 |
piR-hsa-25783.6 | 2 | 5.51 | 5.08E-03 |
piR-hsa-25783 | 1 | 5.44 | 5.63E-03 |
piR-hsa-25783.2 | 16 | 5.37 | 4.65E-03 |
piR-hsa-25783.7 | 5 | 5.16 | 4.11E-03 |
piR-hsa-25783.3 | 16 | 5.09 | 5.63E-03 |
piR-hsa-25783.5 | 17 | 5.08 | 6.42E-03 |
piR-hsa-28390 | 2 | 4.23 | 9.37E-03 |
piR-hsa-28390.1 | 8 | 3.89 | 2.11E-02 |
piR-hsa-1823 | 2 | 3.07 | 2.27E-03 |
piR-hsa-1834 | 17 | −1.77 | 3.29E-02 |
piR-hsa-12789 | Y | −1.94 | 2.96E-02 |
piR-hsa-26685 | M | −2.07 | 3.47E-02 |
piR-hsa-25447 | 18 | −2.31 | 4.40E-03 |
piR-hsa-793 | Y | −2.31 | 1.08E-02 |
piR-hsa-11361 | 9 | −2.71 | 1.13E-02 |
piR-hsa-993 | 5 | −2.72 | 1.46E-03 |
piR-hsa-11360 | 9 | −3.13 | 4.77E-03 |
piR-hsa-26508.6 | X | −3.52 | 6.43E-03 |
piR-hsa-26039 | 17 | −3.58 | 4.56E-04 |
piR-hsa-9010 | 17 | −3.85 | 9.29E-04 |
piR-hsa-27493 | 1 | −4.12 | 1.06E-02 |
piR-hsa-26681 | M | −4.44 | 2.95E-04 |
piR-hsa-26684 | M | −4.44 | 2.95E-04 |
piR-hsa-2153 | 11 | −4.59 | 1.34E-02 |
piR-hsa-27282 | 14 | −5.30 | 2.67E-05 |
piR-hsa-17444 | 20 | −6.07 | 3.45E-06 |
piR-hsa-3200 | 16 | −6.86 | 3.79E-05 |
piR-hsa-1177 | 19 | −7.31 | 5.33E-05 |
piR-hsa-2117 | 7 | −7.41 | 1.76E-06 |
piR-hsa-28478 | 2 | −9.72 | 3.84E-07 |
piR-hsa-25780.9 | 3 | −13.66 | 3.59E-03 |
piR-hsa-25780.1 | 1 | −14.57 | 1.48E-03 |
piR-hsa-25780 | 1 | −14.89 | 1.71E-03 |
piR-hsa-963 | 17 | −16.82 | 2.62E-07 |
piR-hsa-5938 | 3 | −36.11 | 7.78E-07 |
piR-hsa-20613 | 7 | −36.17 | 1.10E-09 |
piR-hsa-5937 | 3 | −36.80 | 1.76E-06 |
piR-hsa-28525 | 4 | −81.85 | 1.90E-09 |
piR-hsa-820 | 2 | −100.92 | 4.08E-07 |
piR-hsa-12759 | 5 | −269.75 | 2.72E-06 |
piR-hsa-952 | 22 | −449.82 | 9.17E-11 |
Table 9.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
piR-hsa-28488 | 6 | 1013.41 | 5.02E-06 |
piR-hsa-7239 | 2 | 791.73 | 9.22E-06 |
piR-hsa-5939 | 12 | 281.36 | 2.40E-06 |
piR-hsa-23655 | 5 | 96.41 | 3.64E-04 |
piR-hsa-6147 | 2 | 25.77 | 2.93E-02 |
piR-hsa-1338 | 11 | 19.90 | 4.58E-06 |
piR-hsa-3178 | 20 | 9.12 | 1.10E-04 |
piR-hsa-27616 | 19 | 6.05 | 1.41E-03 |
piR-hsa-25783.4 | 16 | 4.10 | 1.33E-02 |
piR-hsa-1823 | 2 | 4.06 | 2.63E-03 |
piR-hsa-25783.6 | 2 | 3.78 | 3.36E-02 |
piR-hsa-25783.5 | 17 | 3.46 | 3.59E-02 |
piR-hsa-1834 | 17 | −2.00 | 4.81E-02 |
piR-hsa-993 | 5 | −2.74 | 9.03E-03 |
piR-hsa-26685 | M | −2.79 | 2.16E-02 |
piR-hsa-23317 | 6 | −2.93 | 3.62E-02 |
piR-hsa-26039 | 17 | −2.98 | 1.02E-02 |
piR-hsa-11360 | 9 | −3.62 | 2.78E-02 |
piR-hsa-27493 | 1 | −4.62 | 1.22E-02 |
piR-hsa-17444 | 20 | −4.65 | 3.76E-04 |
piR-hsa-12789 | Y | −4.82 | 3.75E-03 |
piR-hsa-20757.2 | 1 | −5.60 | 4.06E-02 |
piR-hsa-9010 | 17 | −6.88 | 1.47E-04 |
piR-hsa-26684 | M | −7.15 | 1.13E-04 |
piR-hsa-26681 | M | −7.15 | 1.13E-04 |
piR-hsa-3200 | 16 | −7.38 | 7.87E-04 |
piR-hsa-27282 | 14 | −8.31 | 1.56E-06 |
piR-hsa-2153 | 11 | −8.92 | 4.32E-02 |
piR-hsa-2117 | 7 | −11.59 | 1.03E-05 |
piR-hsa-1177 | 19 | −12.56 | 1.64E-05 |
piR-hsa-28478 | 2 | −15.42 | 4.78E-07 |
piR-hsa-25780.9 | 3 | −16.03 | 3.03E-02 |
piR-hsa-25780.1 | 1 | −16.41 | 4.25E-03 |
piR-hsa-25780 | 1 | −16.85 | 2.78E-02 |
piR-hsa-963 | 17 | −20.25 | 8.80E-03 |
piR-hsa-20613 | 7 | −39.75 | 2.27E-07 |
piR-hsa-5937 | 3 | −44.83 | 9.22E-06 |
piR-hsa-5938 | 3 | −45.11 | 5.46E-05 |
piR-hsa-25782.4 | 16 | −94.21 | 7.87E-04 |
piR-hsa-25782.3 | 16 | −104.58 | 3.65E-04 |
piR-hsa-28525 | 4 | −116.32 | 2.79E-10 |
piR-hsa-25782.6 | 2 | −126.18 | 4.15E-04 |
piR-hsa-820 | 2 | −130.03 | 3.65E-04 |
piR-hsa-25782.8 | 6 | −160.04 | 5.10E-04 |
piR-hsa-25782.2 | 16 | −165.67 | 5.83E-05 |
piR-hsa-25782.1 | 16 | −181.07 | 5.46E-05 |
piR-hsa-25782.5 | 17 | −309.27 | 3.15E-05 |
piR-hsa-952 | 22 | −469.05 | 1.02E-04 |
piR-hsa-12759 | 5 | −533.60 | 4.46E-05 |
Table 11.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
piR-hsa-32299 | 1 | 4044.62 | 9.95E-10 |
piR-hsa-23670.1 | 8 | 2335.40 | 4.15E-14 |
piR-hsa-24684.5 | 5 | 2219.85 | 3.09E-08 |
piR-hsa-24684 | 1 | 2072.08 | 7.08E-10 |
piR-hsa-28488 | 6 | 1098.53 | 1.93E-15 |
piR-hsa-7239 | 2 | 949.32 | 2.37E-14 |
piR-hsa-24684.1 | 1 | 761.46 | 2.93E-08 |
piR-hsa-5939 | 12 | 529.51 | 2.33E-15 |
piR-hsa-24684.2 | 1 | 375.35 | 8.29E-08 |
piR-hsa-24684.3 | 11 | 355.01 | 1.96E-07 |
piR-hsa-24684.7 | 5 | 331.73 | 3.48E-06 |
piR-hsa-24684.8 | 6 | 241.61 | 7.96E-07 |
piR-hsa-24684.4 | 5 | 228.88 | 2.41E-07 |
piR-hsa-23655 | 5 | 106.32 | 2.38E-06 |
piR-hsa-24684.6 | 5 | 88.62 | 4.13E-05 |
piR-hsa-5067.1 | 3 | 46.48 | 1.07E-08 |
piR-hsa-5067.4 | 6 | 44.68 | 3.71E-06 |
piR-hsa-12488 | 11 | 39.49 | 1.55E-06 |
piR-hsa-12488.1 | M | 35.19 | 3.88E-06 |
piR-hsa-6147 | 2 | 30.46 | 1.03E-03 |
piR-hsa-26131 | 7 | 20.96 | 5.50E-04 |
piR-hsa-28378.6 | 6 | 19.88 | 4.16E-08 |
piR-hsa-28374.6 | 6 | 19.88 | 4.16E-08 |
piR-hsa-1338 | 11 | 19.63 | 4.37E-09 |
piR-hsa-28378.2 | 5 | 18.44 | 6.16E-08 |
piR-hsa-28374.2 | 5 | 18.44 | 6.16E-08 |
piR-hsa-28378 | 12 | 18.44 | 3.01E-08 |
piR-hsa-28374 | 12 | 18.44 | 3.01E-08 |
piR-hsa-28374.4 | 6 | 18.29 | 3.90E-08 |
piR-hsa-28378.4 | 6 | 18.29 | 3.90E-08 |
piR-hsa-28374.5 | 6 | 17.33 | 3.85E-08 |
piR-hsa-28378.5 | 6 | 17.33 | 3.85E-08 |
piR-hsa-28374.1 | 12 | 17.22 | 4.14E-08 |
piR-hsa-28378.1 | 12 | 17.22 | 4.14E-08 |
piR-hsa-23786 | 20 | 16.93 | 4.71E-12 |
piR-hsa-28374.3 | 6 | 16.31 | 4.23E-08 |
piR-hsa-28378.3 | 6 | 16.31 | 4.23E-08 |
piR-hsa-26754 | 5 | 14.19 | 8.68E-05 |
piR-hsa-3178 | 20 | 12.26 | 8.67E-07 |
piR-hsa-28487 | 2 | 9.95 | 3.28E-08 |
piR-hsa-15023.1 | M | 8.68 | 8.72E-04 |
piR-hsa-15023 | 8 | 8.24 | 8.71E-04 |
piR-hsa-28116.3 | 6 | 7.13 | 2.75E-02 |
piR-hsa-28116.1 | 17 | 7.05 | 3.12E-02 |
piR-hsa-28116.2 | 6 | 6.84 | 3.45E-02 |
piR-hsa-28116.7 | 6 | 6.73 | 3.72E-02 |
piR-hsa-28116.6 | 6 | 6.64 | 4.50E-02 |
piR-hsa-28116.4 | 6 | 6.48 | 2.58E-02 |
piR-hsa-28116.8 | 6 | 6.36 | 2.91E-02 |
piR-hsa-28116.9 | 6 | 6.15 | 3.63E-02 |
piR-hsa-28190 | 11 | 6.13 | 6.32E-05 |
piR-hsa-2155 | M | 5.29 | 4.29E-02 |
piR-hsa-27616 | 19 | 4.98 | 5.27E-07 |
piR-hsa-7193.2 | 1 | 4.61 | 7.08E-03 |
piR-hsa-7193.3 | 15 | 4.49 | 1.39E-02 |
piR-hsa-7193.6 | 2 | 4.44 | 1.48E-02 |
piR-hsa-7193.5 | 15 | 4.42 | 4.51E-03 |
piR-hsa-7193.1 | 1 | 4.33 | 7.65E-03 |
piR-hsa-7193.4 | 15 | 4.30 | 7.43E-03 |
piR-hsa-23619.1 | 16 | 4.23 | 1.70E-02 |
piR-hsa-25783.4 | 16 | 4.20 | 1.61E-02 |
piR-hsa-23619.4 | 6 | 4.16 | 1.18E-02 |
piR-hsa-7193 | 1 | 4.12 | 1.39E-02 |
piR-hsa-23619 | 1 | 4.09 | 2.36E-02 |
piR-hsa-25783.6 | 2 | 4.05 | 2.06E-02 |
piR-hsa-25783.8 | 6 | 4.05 | 1.58E-02 |
piR-hsa-23619.3 | 5 | 4.04 | 2.88E-02 |
piR-hsa-25783.1 | 16 | 4.03 | 1.86E-02 |
piR-hsa-28390 | 2 | 3.98 | 3.29E-03 |
piR-hsa-25783 | 1 | 3.98 | 2.15E-02 |
piR-hsa-14647 | 9 | 3.87 | 2.85E-04 |
piR-hsa-25783.2 | 16 | 3.86 | 2.52E-02 |
piR-hsa-23619.2 | 5 | 3.82 | 2.04E-02 |
piR-hsa-28875 | 2 | 3.80 | 2.40E-02 |
piR-hsa-28875.1 | M | 3.79 | 2.91E-02 |
piR-hsa-25783.3 | 16 | 3.75 | 2.06E-02 |
piR-hsa-25783.7 | 5 | 3.69 | 2.91E-02 |
piR-hsa-25783.5 | 17 | 3.64 | 2.86E-02 |
piR-hsa-28390.1 | 8 | 3.62 | 4.46E-03 |
piR-hsa-1823 | 2 | 3.38 | 9.34E-04 |
piR-hsa-1742 | 1 | 2.95 | 8.96E-05 |
piR-hsa-28319.1 | 9 | 1.85 | 1.01E-02 |
piR-hsa-28319 | 9 | 1.80 | 1.14E-02 |
piR-hsa-28382 | 12 | −1.63 | 4.36E-02 |
piR-hsa-26686 | M | −1.84 | 2.03E-02 |
piR-hsa-11362 | 21 | −1.88 | 3.47E-02 |
piR-hsa-9010 | 17 | −1.88 | 1.48E-02 |
piR-hsa-993 | 5 | −1.90 | 9.08E-03 |
piR-hsa-20266 | 5 | −2.29 | 2.15E-03 |
piR-hsa-26685 | M | −2.35 | 2.99E-03 |
piR-hsa-20266.1 | M | −2.38 | 9.82E-04 |
piR-hsa-1043 | 4 | −2.40 | 9.82E-04 |
piR-hsa-24672.3 | 6 | −2.41 | 6.97E-03 |
piR-hsa-24672 | 1 | −2.43 | 5.81E-03 |
piR-hsa-24672.4 | 6 | −2.44 | 7.14E-03 |
piR-hsa-24672.1 | 1 | −2.45 | 6.07E-03 |
piR-hsa-23317 | 6 | −2.65 | 9.61E-03 |
piR-hsa-28212.2 | 7 | −2.69 | 6.82E-04 |
piR-hsa-28212.1 | 11 | −2.70 | 6.10E-04 |
piR-hsa-25447 | 18 | −2.82 | 9.80E-05 |
piR-hsa-28212 | 1 | −2.82 | 2.94E-04 |
piR-hsa-27282 | 14 | −2.99 | 1.91E-04 |
piR-hsa-25780.10 | 4 | −3.11 | 2.88E-02 |
piR-hsa-26039 | 17 | −3.30 | 4.84E-05 |
piR-hsa-17444 | 20 | −3.46 | 7.18E-06 |
piR-hsa-11361 | 9 | −3.66 | 3.52E-03 |
piR-hsa-26508.6 | X | −3.66 | 2.50E-03 |
piR-hsa-2153 | 11 | −4.00 | 2.00E-03 |
piR-hsa-20757.2 | 1 | −4.30 | 3.05E-02 |
piR-hsa-26681 | M | −4.36 | 1.77E-05 |
piR-hsa-26684 | M | −4.36 | 1.77E-05 |
piR-hsa-2117 | 7 | −5.03 | 7.76E-06 |
piR-hsa-11360 | 9 | −5.05 | 1.59E-04 |
piR-hsa-1177 | 19 | −5.27 | 2.17E-06 |
piR-hsa-27493 | 1 | −5.27 | 7.05E-04 |
piR-hsa-3200 | 16 | −7.10 | 7.96E-07 |
piR-hsa-20613 | 7 | −7.45 | 9.32E-07 |
piR-hsa-28478 | 2 | −10.34 | 4.94E-11 |
piR-hsa-963 | 17 | −11.58 | 6.23E-08 |
piR-hsa-25780.1 | 1 | −11.82 | 2.13E-04 |
piR-hsa-25780 | 1 | −11.96 | 2.34E-04 |
piR-hsa-25780.9 | 3 | −12.16 | 3.07E-04 |
piR-hsa-5936 | 5 | −20.70 | 3.07E-10 |
piR-hsa-5937 | 3 | −51.29 | 3.07E-10 |
piR-hsa-5938 | 3 | −56.84 | 4.68E-09 |
piR-hsa-28525 | 4 | −57.64 | 4.37E-06 |
piR-hsa-820 | 2 | −78.24 | 9.30E-06 |
piR-hsa-952 | 22 | −517.94 | 1.14E-19 |
Large data from all five groups was placed in a Venn diagram (Fig. 5F), which showed, 30 piRs were commonly expressed in all groups; whereas six in cirrhosis, seven in HGDN, and 52 in HCC were uniquely expressed (Fig. 5F). Interestingly, we could not determine piRs linked specifically to LGDN and eHCC. There were several piRs commonly expressed between groups; specifically, 14 in LGDN and HCC, 10 in cirrhosis and HCC, 11 in cirrhosis and eHCC, and eight in cirrhosis, HGDN, eHCC, and HCC (Fig. 5F). We also prepared a Circos Plot for comprehensive visualization of differentially expressed piRs, with chromosome number and location (Fig. 5G). After, plugging the data into Circos Plot, we found chromosomes 1, 2, 5, 6, and 22 were the most enriched chromosomes in all five groups (Fig. 5G).
Differential Expression of lncRNA in Cirrhosis, LGDN, HGDN, eHCC, and HCC Tissue Samples
We further analyzed data for long non-coding RNAs using lncRNA annotation on small RNA sequencing data and calculated differential expression in all five groups (Fig. 6A–E, Tables 12–14, Supplimetery Tables 1 and 2). Our annotation identified 192 lncRNAs in cirrhosis (42 upregulated and 150 downregulated; Fig. 6A, Table 12), 180 lncRNAs in LGDN (53 upregulated and 127 downregulated; Fig. 6B, Supplimentery Table 1), 150 lncRNAs in HGDN (24 upregulated and 126 downregulated; Fig. 6C, Table 13), 160 lncRNAs in eHCC (24 upregulated and 136 downregulated; Fig. 6D, Table 14), and 225 lncRNAs in HCC (96 upregulated and 129 downregulated; Fig. 6E, Supplimentery Table 2). The top five upregulated lncRNAs in cirrhosis (Table 12) were: lnc-C21orf67-10 (23661-fold), lnc-CRK-3 (19138-fold), lnc-FBXO11-7 (5354-fold), lnc-GCNT1-4 (383-fold, 5 various transcripts with fold change range 279–383), and HAGLR:1 (260-fold); whereas, lnc-AC022098.1-1:10 (343-fold), lnc-HSD17B10-3 (231-fold), lnc-NEDD4L-1 (42-fold), GAS5:43 (41-fold), and lnc-CTD-2144E22.5.1-20 (36-fold) were downregulated. The top five upregulated lncRNAs in LGDN (Supplimentery Table 1) were: lnc-CRK-3 (1830-fold), GCNT1-4 (355-fold, five various transcripts with fold change range 339–383), lnc-ADCY10-1 (271-fold), lnc-UBC-3 (237-fold), and lnc-TRIM27-18 (172-fold). The top five downregulated were: lnc-AC022098.1-1:10 (756-fold), SNHG6:15 (144-fold), GAS5 (124-fold, three transcripts), lnc-HSD17B10-3 (104-fold), and lnc-CCNB1IP1-1 (103-fold). The top five upregulated lncRNAs in HGDN (Table 13) were: GCNT1-4 (307-fold, top 5 various transcripts with fold change range 295–307), lnc-UBC-3 (293-fold), lnc-TRIM27-18 (238-fold), LNC00273:8 (34-fold), and lnc-FNBP1L-2 (18-fold) and the top five downregulated were: lnc-AC022098.1-1:10 (1603-fold), GAS5 (685-fold, four transcripts with fold change ranging from 51–685), SNHG6:15 (409-fold), lnc-HSD17B10-3 (105-fold), and lnc-CTD-2144E22.5.1-20 (89-fold). The top five upregulated lncRNAs in eHCC (Table 14) were: lnc-CRK-3 (6385-fold), GCNT1-4 (290-fold, continue 5 various transcripts with fold change range 237–290), HAGLR (251-fold), lnc-UBC-3 (202-fold), and lnc-TRIM27-18 (171-fold); whereas the top five downregulated were: lnc-MBNL2-3 (1457-fold), LINC01021:16 (1317-fold), GAS5 (815-fold, multiple transcript types), SNHG1:60 (694-fold), and lnc-AC022098.1-1:10 (577-fold). The top five upregulated lncRNAs in HCC (Supplimentery Table 2) were: lnc-CCDC167-2 (1 million-fold), lnc-TPTE-3 (18378-fold), lnc-C21orf67-10 (9271-fold), lnc-TMEM8A-1 (6308-fold), and lnc-CRK-3 (3027-fold), with downregulation seen in: lnc-SNHG6:15 (99-fold), HSD17B10-3 (65-fold), lnc-CCNB1IP1-1 (50-fold), GAS5 (45-fold, multiple transcripts), and lnc-ARHGEF6-4 (28-fold). Further investigation is needed to determine their importance in HCC development.
Table 12.
lncRNA ID | Chromosome | Fold change | FDR |
---|---|---|---|
lnc-C21orf67-10:1 | 21 | 23661.18 | 1.25E-09 |
lnc-CRK-3:2 | 17 | 19137.71 | 4.54E-08 |
lnc-FBXO11-7:1 | 2 | 5354.15 | 1.25E-09 |
lnc-GCNT1-4:6 | 9 | 382.70 | 4.77E-08 |
lnc-GCNT1-4:5 | 9 | 320.01 | 8.81E-07 |
lnc-GCNT1-4:2 | 9 | 284.32 | 5.92E-05 |
lnc-GCNT1-4:3 | 9 | 284.07 | 4.24E-05 |
lnc-GCNT1-4:4 | 9 | 278.80 | 8.29E-05 |
HAGLR:1 | 2 | 259.55 | 2.06E-06 |
HAGLR:31 | 2 | 259.36 | 2.06E-06 |
lnc-ADCY10-1:1 | 1 | 199.46 | 3.12E-06 |
lnc-UBC-3:1 | 12 | 146.21 | 8.81E-07 |
lnc-TRIM27-18:1 | 6 | 68.97 | 7.70E-04 |
lnc-AC106017.1.1-2:1 | 17 | 52.61 | 1.30E-09 |
lnc-FNBP1L-2:1 | 1 | 36.38 | 3.18E-05 |
lnc-FCGR3A-3:1 | 1 | 30.45 | 3.64E-08 |
lnc-ZNF391-5:2 | 6 | 26.39 | 2.34E-07 |
lnc-AC102948.1.1-4:1 | 17 | 25.97 | 3.76E-07 |
lnc-ECHDC1-1:1 | 6 | 16.78 | 4.18E-04 |
lnc-MAP1LC3B-7:1 | 16 | 16.24 | 4.41E-06 |
lnc-PRRC2C-5:1 | 1 | 15.40 | 5.83E-05 |
lnc-C6orf100-12:1 | 6 | 15.25 | 9.73E-06 |
LIMD1-AS1:6 | 3 | 14.15 | 1.96E-05 |
lnc-GNGT2-1:2 | 17 | 14.13 | 5.72E-04 |
lnc-GPR39-7:2 | 2 | 11.30 | 1.17E-02 |
SNHG1:34 | 11 | 8.88 | 5.63E-05 |
lnc-TMPO-1:1 | 12 | 6.71 | 4.40E-03 |
lnc-HIST1H2BI-2:2 | 6 | 6.70 | 8.37E-04 |
lnc-NARF-2:2 | 17 | 6.53 | 7.74E-04 |
lnc-SAG-4:1 | 2 | 6.35 | 6.94E-03 |
lnc-TRIM7-2:5 | 5 | 5.95 | 7.95E-03 |
lnc-PARVG-4:1 | 22 | 4.65 | 1.98E-03 |
MIR22HG:35 | 17 | 4.37 | 4.94E-02 |
MIR22HG:18 | 17 | 4.37 | 4.94E-02 |
MIR22HG:24 | 17 | 4.32 | 4.77E-02 |
lnc-GRAP-1:1 | 17 | 4.27 | 4.96E-04 |
lnc-AC007952.2.1-2:1 | 17 | 4.26 | 5.31E-04 |
MIR22HG:47 | 17 | 4.25 | 4.87E-02 |
lnc-AC007952.1.1-3:1 | 17 | 4.21 | 4.04E-04 |
lnc-AC007952.2-2:3 | 17 | 4.16 | 4.51E-04 |
lnc-AC007952.2-2:1 | 17 | 4.14 | 4.59E-04 |
lnc-METTL12-1:2 | 11 | 1.97 | 3.70E-02 |
DLEU2:20 | 13 | −1.17 | 4.93E-02 |
GAS5:42 | 1 | −1.31 | 3.12E-02 |
GAS5:83 | 1 | −1.32 | 3.08E-02 |
lnc-GPC3-1:1 | X | −1.49 | 2.81E-02 |
lnc-AC027763.2.1-1:2 | 17 | −1.56 | 2.42E-02 |
lnc-ZFAT-1:6 | 8 | −1.57 | 4.35E-02 |
lnc-MON2-2:8 | 12 | −1.58 | 3.34E-02 |
lnc-MON2-2:10 | 12 | −1.60 | 3.08E-02 |
lnc-MON2-2:2 | 12 | −1.60 | 3.08E-02 |
lnc-KNG1-2:6 | 3 | −1.61 | 3.90E-02 |
lnc-COPG2-3:1 | 7 | −1.62 | 4.77E-02 |
SNHG16:42 | 17 | −1.74 | 3.16E-02 |
lnc-TPTE-3:4 | 21 | −1.86 | 8.02E-03 |
lnc-CTR9-1:2 | 11 | −2.06 | 9.05E-03 |
lnc-FLOT2-1:1 | 17 | −2.07 | 3.17E-02 |
lnc-SNURF-1:73 | 15 | −2.14 | 2.67E-02 |
lnc-C9orf100-1:1 | 9 | −2.15 | 4.22E-03 |
lnc-IRS4-2:1 | X | −2.22 | 4.25E-03 |
lnc-SNURF-1:17 | 15 | −2.50 | 8.46E-03 |
lnc-HIATL1-20:1 | 9 | −2.55 | 7.27E-03 |
lnc-SNAPC5-4:3 | 15 | −2.57 | 5.11E-03 |
lnc-TRIM52-2:1 | 5 | −2.61 | 3.17E-03 |
lnc-RPL13A-1:5 | 19 | −2.65 | 3.05E-03 |
lnc-AC106017.1.1-2:2 | 17 | −2.70 | 5.11E-03 |
LINC00273:1 | 16 | −2.71 | 1.04E-03 |
LINC00273:11 | 16 | −2.77 | 3.02E-03 |
lnc-GRAP-1:2 | 17 | −2.83 | 3.64E-02 |
lnc-TRIM59-2:1 | 3 | −2.96 | 1.45E-03 |
MIR210HG:7 | 11 | −2.96 | 7.50E-03 |
SNHG21:29 | 15 | −3.01 | 2.42E-02 |
lnc-GCNT1-4:1 | 9 | −3.04 | 3.40E-03 |
lnc-PLA2G1B-2:3 | 12 | −3.13 | 3.40E-03 |
FTX:29 | X | −3.18 | 8.08E-03 |
lnc-HEPH-1:1 | X | −3.29 | 2.27E-02 |
lnc-HES7-1:1 | 17 | −3.29 | 1.61E-02 |
lnc-TTLL10-3:9 | 1 | −3.42 | 3.14E-02 |
lnc-CCNB1IP1-1:4 | 14 | −3.42 | 4.32E-02 |
lnc-ERAL1-1:1 | 17 | −3.43 | 1.65E-02 |
LINC-PINT:28 | 7 | −3.46 | 7.20E-03 |
lnc-COL4A5-3:1 | X | −3.46 | 6.64E-04 |
LINC-PINT:29 | 7 | −3.48 | 4.72E-03 |
lnc-KIF20B-3:1 | 10 | −3.54 | 2.92E-03 |
lnc-FGA-1:1 | 4 | −3.57 | 2.25E-04 |
SNHG1:44 | 11 | −3.57 | 1.08E-03 |
SNHG1:4 | 11 | −3.57 | 1.08E-03 |
SNHG19:3 | 16 | −3.63 | 5.35E-04 |
lnc-RP4-695O20__B.10.1-3:10 | 22 | −3.75 | 2.66E-03 |
lnc-GPR39-10:3 | 2 | −3.75 | 1.98E-04 |
lnc-RP4-695O20__B.10.1-3:9 | 22 | −3.75 | 2.66E-03 |
lnc-RP4-695O20__B.10.1-3:12 | 22 | −3.75 | 2.66E-03 |
SNHG22:3 | 18 | −3.82 | 2.20E-04 |
UBA6-AS1:26 | 4 | −3.90 | 4.16E-04 |
SNHG5:47 | 6 | −3.92 | 6.02E-04 |
SNHG5:5 | 6 | −3.92 | 6.02E-04 |
lnc-CTD-2144E22.5.1-19:1 | 16 | −3.93 | 2.31E-02 |
lnc-VMP1-3:3 | 17 | −4.24 | 2.10E-03 |
DNM3OS:3 | 1 | −4.27 | 2.92E-03 |
LINC00472:10 | 6 | −4.33 | 2.57E-03 |
lnc-SLC15A4-24:1 | 12 | −4.41 | 9.30E-06 |
lnc-AL669831.1-12:2 | 1 | −4.46 | 2.20E-04 |
lnc-C11orf54-1:1 | 11 | −4.50 | 1.65E-02 |
lnc-AC007952.1.1-3:2 | 17 | −4.62 | 8.97E-03 |
GAS5:68 | 1 | −4.64 | 5.35E-04 |
lnc-CUL1-5:1 | 7 | −4.68 | 6.37E-04 |
lnc-AL669831.1-14:1 | 1 | −4.78 | 2.26E-02 |
lnc-TSPY10-14:1 | Y | −4.78 | 4.41E-05 |
lnc-KLK1-2:3 | 19 | −4.90 | 2.25E-04 |
lnc-KIF2C-2:1 | 1 | −5.12 | 2.17E-04 |
lnc-C19orf57-6:5 | 19 | −5.31 | 1.09E-03 |
lnc-PDIA4-1:1 | 7 | −5.34 | 4.07E-04 |
lnc-GPR39-7:1 | 2 | −5.46 | 2.64E-05 |
lnc-LRR1-1:1 | 14 | −5.49 | 1.21E-04 |
MIR503HG:16 | X | −5.53 | 1.18E-02 |
lnc-LRR1-1:4 | 14 | −5.54 | 1.10E-04 |
lnc-HIST1H2AH-5:1 | 6 | −5.57 | 5.50E-03 |
lnc-SLC25A30-3:1 | 13 | −5.59 | 1.55E-02 |
lnc-GPR39-10:2 | 2 | −5.61 | 6.27E-06 |
MIR503HG:17 | X | −5.62 | 1.01E-02 |
lnc-FGG-2:1 | 4 | −5.63 | 5.83E-05 |
lnc-NEMF-1:4 | 14 | −5.67 | 1.17E-04 |
lnc-AC007952.2.1-2:2 | 17 | −5.92 | 7.20E-03 |
MIR193BHG:18 | 16 | −6.01 | 1.27E-02 |
lnc-AFP-1:2 | 4 | −6.14 | 1.85E-05 |
lnc-AFP-3:1 | 4 | −6.17 | 8.71E-06 |
lnc-ANKRD34B-4:2 | 5 | −6.22 | 1.51E-04 |
lnc-AUTS2-6:1 | 7 | −6.55 | 1.28E-06 |
lnc-KNG1-2:8 | 3 | −6.65 | 2.69E-04 |
MIR99AHG:51 | 21 | −6.83 | 1.98E-04 |
MIR99AHG:50 | 21 | −6.83 | 1.98E-04 |
MIR99AHG:63 | 21 | −6.83 | 1.98E-04 |
MIR99AHG:42 | 21 | −6.84 | 1.98E-04 |
lnc-DUOX1-2:1 | 15 | −6.94 | 2.92E-03 |
lnc-DUOXA1-2:1 | 15 | −6.97 | 2.92E-03 |
lnc-DUOXA1-1:1 | 15 | −7.02 | 2.71E-03 |
lnc-ZBTB37-2:1 | 1 | −7.11 | 4.82E-04 |
GAS5:16 | 1 | −7.16 | 7.55E-03 |
lnc-SYT10-3:5 | 12 | −7.18 | 1.04E-05 |
LINC01138:11 | 1 | −7.26 | 5.98E-06 |
lnc-RABGGTB-1:6 | 1 | −7.59 | 5.68E-05 |
lnc-HNRNPA2B1-10:4 | 7 | −7.75 | 1.47E-04 |
lnc-AC006156.1-11:1 | Y | −7.76 | 9.35E-06 |
lnc-DAO-3:1 | 12 | −7.76 | 1.85E-05 |
lnc-CFH-2:1 | 1 | −7.78 | 1.66E-06 |
lnc-VSTM5-1:13 | 11 | −8.06 | 1.98E-04 |
lnc-SNURF-1:2 | 15 | −8.07 | 3.64E-03 |
lnc-AUTS2-6:2 | 7 | −8.45 | 9.30E-06 |
lnc-NEK8-2:1 | 17 | −8.52 | 4.33E-05 |
SNHG1:25 | 11 | −8.66 | 4.22E-03 |
LRRC75A-AS1:49 | 17 | −8.93 | 1.04E-04 |
MIR17HG:6 | 13 | −9.59 | 9.21E-05 |
lnc-SPG7-2:3 | 16 | −9.70 | 2.94E-05 |
ZFAS1:23 | 20 | −9.84 | 4.68E-05 |
lnc-AK3-1:1 | 9 | −9.89 | 2.69E-04 |
lnc-TPTE-3:5 | 21 | −9.93 | 2.64E-02 |
SNHG1:12 | 11 | −10.01 | 3.40E-03 |
lnc-ZNF169-7:2 | 9 | −10.29 | 2.64E-04 |
lnc-APAF1-3:1 | 12 | −10.43 | 5.36E-03 |
lnc-SNAPC5-4:1 | 15 | −10.61 | 1.26E-05 |
lnc-SNAPC5-4:2 | 15 | −10.74 | 9.76E-03 |
lnc-SLC3A2-6:1 | 11 | −11.22 | 7.37E-05 |
lnc-SNURF-1:92 | 15 | −12.62 | 2.89E-05 |
lnc-SNURF-1:95 | 15 | −12.62 | 2.96E-05 |
SNHG1:1 | 11 | −13.61 | 6.63E-06 |
lnc-AFP-2:1 | 4 | −14.05 | 6.73E-07 |
SNHG1:59 | 11 | −14.65 | 3.37E-03 |
lnc-ZNF169-7:7 | 9 | −15.03 | 1.52E-03 |
lnc-VSTM5-1:10 | 11 | −16.65 | 1.75E-03 |
lnc-MOS-1:2 | 8 | −17.57 | 2.77E-06 |
lnc-HAUS5-3:2 | 19 | −18.31 | 2.94E-07 |
lnc-HAUS5-3:1 | 19 | −18.35 | 2.94E-07 |
lnc-MINA-3:5 | 3 | −19.52 | 1.41E-03 |
SNHG8:14 | 4 | −19.53 | 1.11E-03 |
lnc-RPL17-2:4 | 18 | −21.13 | 3.79E-05 |
lnc-MYO16-7:1 | 13 | −21.97 | 3.76E-07 |
lnc-CRKL-2:1 | 22 | −22.43 | 4.38E-07 |
lnc-VSTM5-1:7 | 11 | −23.84 | 5.36E-04 |
LINC00910:16 | 17 | −25.81 | 6.63E-06 |
LINC00910:1 | 17 | −26.20 | 5.76E-06 |
lnc-ARHGEF6-4:1 | X | −28.71 | 4.77E-08 |
MIR17HG:5 | 13 | −28.92 | 1.14E-03 |
LRRC75A-AS1:41 | 17 | −29.36 | 9.83E-05 |
lnc-CCNB1IP1-1:2 | 14 | −31.52 | 1.91E-05 |
lnc-TPTE-3:9 | 21 | −33.36 | 7.98E-04 |
LRRC75A-AS1:36 | 17 | −34.20 | 2.52E-06 |
lnc-TMEM132C-11:1 | 12 | −34.56 | 1.45E-05 |
lnc-CTD-2144E22.5.1-20:1 | 16 | −35.71 | 1.21E-03 |
GAS5:43 | 1 | −41.26 | 2.89E-05 |
lnc-NEDD4L-1:6 | 18 | −41.69 | 1.28E-06 |
lnc-HSD17B10-3:1 | X | −230.89 | 1.85E-05 |
lnc-AC022098.1-1:10 | 19 | −343.09 | 2.34E-07 |
Table 14.
lncRNA ID | Chromosome | Fold change | FDR |
---|---|---|---|
lnc-CRK-3:2 | 17 | 6384.96 | 9.03E-05 |
lnc-GCNT1-4:6 | 9 | 289.82 | 1.66E-08 |
lnc-GCNT1-4:5 | 9 | 269.34 | 1.66E-08 |
HAGLR:1 | 2 | 251.27 | 3.02E-03 |
lnc-GCNT1-4:2 | 9 | 240.21 | 1.33E-07 |
lnc-GCNT1-4:3 | 9 | 237.82 | 1.33E-07 |
lnc-GCNT1-4:4 | 9 | 237.45 | 1.33E-07 |
lnc-UBC-3:1 | 12 | 202.61 | 4.21E-05 |
lnc-TRIM27-18:1 | 6 | 170.61 | 4.91E-03 |
lnc-AC106017.1.1-2:1 | 17 | 51.74 | 2.12E-05 |
lnc-FNBP1L-2:1 | 1 | 24.51 | 2.18E-03 |
lnc-GNGT2-1:2 | 17 | 23.07 | 4.17E-04 |
LINC00273:8 | 16 | 20.55 | 1.80E-02 |
lnc-AC102948.1.1-4:1 | 17 | 15.69 | 8.11E-05 |
LIMD1-AS1:6 | 3 | 15.67 | 3.53E-04 |
lnc-PRRC2C-5:1 | 1 | 15.57 | 1.02E-03 |
lnc-ZNF391-5:2 | 6 | 14.67 | 1.26E-03 |
lnc-GPR39-7:2 | 2 | 11.36 | 1.21E-03 |
lnc-ZNF133-3:1 | 20 | 5.79 | 3.20E-02 |
lnc-SAG-4:1 | 2 | 4.05 | 1.22E-02 |
MIR22HG:35 | 17 | 2.84 | 1.32E-02 |
MIR22HG:18 | 17 | 2.84 | 1.32E-02 |
MIR22HG:24 | 17 | 2.84 | 1.16E-02 |
MIR22HG:47 | 17 | 2.83 | 1.19E-02 |
FTX:29 | X | −1.01 | 4.72E-02 |
lnc-SLC25A30-3:1 | 13 | −1.61 | 4.56E-02 |
LINC-PINT:28 | 7 | −1.66 | 4.39E-02 |
lnc-VMP1-3:3 | 17 | −1.70 | 3.20E-02 |
LINC-PINT:29 | 7 | −1.74 | 3.44E-02 |
lnc-C9orf100-1:1 | 9 | −1.90 | 3.30E-02 |
lnc-RPL13A-1:5 | 19 | −1.97 | 3.73E-02 |
LINC00472:10 | 6 | −1.98 | 2.50E-02 |
lnc-SNURF-1:17 | 15 | −1.99 | 4.63E-02 |
SNHG16:42 | 17 | −2.01 | 2.10E-02 |
lnc-KIF20B-3:1 | 10 | −2.02 | 3.04E-02 |
lnc-ZNF169-7:7 | 9 | −2.07 | 2.64E-02 |
MIR193BHG:18 | 16 | −2.12 | 2.17E-02 |
lnc-FPR2-1:35 | 19 | −2.27 | 2.20E-02 |
LINC00324:3 | 17 | −2.30 | 1.37E-02 |
lnc-SNAPC5-4:3 | 15 | −2.35 | 2.63E-02 |
lnc-SLC15A4-24:1 | 12 | −2.36 | 1.32E-02 |
lnc-RP4-695O20__B.10.1-3:9 | 22 | −2.36 | 1.01E-02 |
lnc-RP4-695O20__B.10.1-3:12 | 22 | −2.37 | 9.86E-03 |
lnc-RP4-695O20__B.10.1-3:10 | 22 | −2.37 | 9.86E-03 |
SNHG1:4 | 11 | −2.41 | 1.50E-02 |
SNHG1:44 | 11 | −2.41 | 1.50E-02 |
lnc-MON2-2:8 | 12 | −2.43 | 1.19E-02 |
lnc-PLA2G1B-2:3 | 12 | −2.45 | 2.44E-02 |
lnc-MON2-2:10 | 12 | −2.45 | 1.10E-02 |
lnc-MON2-2:2 | 12 | −2.45 | 1.13E-02 |
lnc-SYT10-3:5 | 12 | −2.46 | 1.38E-02 |
lnc-NEMF-1:4 | 14 | −2.49 | 1.75E-02 |
lnc-CUL1-5:1 | 7 | −2.58 | 1.09E-02 |
lnc-TRIM52-2:1 | 5 | −2.62 | 9.07E-03 |
lnc-ANKRD34B-4:2 | 5 | −2.68 | 9.57E-03 |
MIR210HG:7 | 11 | −2.75 | 1.99E-02 |
LINC00273:1 | 16 | −2.89 | 1.49E-03 |
UBA6-AS1:26 | 4 | −2.97 | 3.85E-03 |
lnc-SNURF-1:73 | 15 | −3.03 | 1.67E-02 |
lnc-LRR1-1:1 | 14 | −3.07 | 5.99E-03 |
lnc-LRR1-1:4 | 14 | −3.10 | 5.70E-03 |
lnc-TRIM59-2:1 | 3 | −3.19 | 7.10E-04 |
lnc-CRKL-2:1 | 22 | −3.22 | 3.83E-02 |
lnc-TSPY10-14:1 | Y | −3.29 | 2.12E-03 |
lnc-NEK8-2:1 | 17 | −3.33 | 8.39E-03 |
SNHG19:3 | 16 | −3.36 | 1.54E-03 |
lnc-GCNT1-4:1 | 9 | −3.38 | 7.74E-03 |
lnc-ZNF169-7:2 | 9 | −3.49 | 4.90E-03 |
lnc-CFH-2:1 | 1 | −3.52 | 3.31E-03 |
lnc-AC106017.1.1-2:2 | 17 | −3.53 | 2.10E-03 |
lnc-HNRNPA2B1-10:4 | 7 | −3.57 | 6.41E-03 |
lnc-MINA-3:5 | 3 | −3.63 | 2.18E-02 |
lnc-HEPH-1:1 | X | −3.70 | 1.28E-02 |
lnc-AUTS2-6:1 | 7 | −3.72 | 2.54E-04 |
lnc-GPR39-10:3 | 2 | −3.79 | 2.22E-04 |
lnc-KNG1-2:8 | 3 | −3.80 | 7.11E-03 |
SNHG5:47 | 6 | −3.83 | 1.35E-03 |
SNHG5:5 | 6 | −3.83 | 1.35E-03 |
lnc-TTLL10-3:9 | 1 | −3.88 | 1.04E-02 |
lnc-GPR39-7:1 | 2 | −3.91 | 6.00E-04 |
lnc-FGG-2:1 | 4 | −3.97 | 1.01E-03 |
SNHG22:3 | 18 | −4.08 | 2.79E-03 |
lnc-KLK1-2:3 | 19 | −4.24 | 5.23E-03 |
lnc-DUOX1-2:1 | 15 | −4.38 | 4.95E-02 |
lnc-CTD-2144E22.5.1-19:1 | 16 | −4.39 | 5.42E-03 |
lnc-DUOXA1-1:1 | 15 | −4.44 | 4.91E-02 |
lnc-COL4A5-3:1 | X | −4.50 | 2.74E-02 |
lnc-C19orf57-6:5 | 19 | −4.51 | 3.02E-03 |
lnc-C11orf54-1:1 | 11 | −4.55 | 1.20E-03 |
MIR17HG:6 | 13 | −4.58 | 2.26E-03 |
lnc-KIF2C-2:1 | 1 | −4.65 | 1.27E-03 |
ZFAS1:23 | 20 | −4.80 | 1.49E-03 |
GAS5:68 | 1 | −4.82 | 1.03E-03 |
lnc-GPR39-10:2 | 2 | −4.89 | 8.14E-05 |
lnc-FLOT2-1:1 | 17 | −4.95 | 1.70E-02 |
lnc-AL669831.1-14:1 | 1 | −4.99 | 2.43E-04 |
lnc-VSTM5-1:13 | 11 | −5.01 | 3.83E-03 |
lnc-TPTE-3:9 | 21 | −5.16 | 7.51E-03 |
DNM3OS:3 | 1 | −5.18 | 2.18E-03 |
lnc-AL669831.1-12:2 | 1 | −5.19 | 1.30E-04 |
lnc-MSH3-2:1 | 5 | −5.54 | 1.78E-02 |
lnc-VSTM5-1:10 | 11 | −5.73 | 1.71E-02 |
lnc-AUTS2-6:2 | 7 | −5.75 | 7.10E-04 |
lnc-AFP-3:1 | 4 | −5.79 | 4.31E-05 |
lnc-HAUS5-3:2 | 19 | −5.89 | 1.21E-03 |
lnc-HAUS5-3:1 | 19 | −5.90 | 1.23E-03 |
SNHG8:14 | 4 | −6.16 | 1.01E-02 |
lnc-AK3-1:1 | 9 | −6.43 | 2.40E-03 |
lnc-ZBTB37-2:1 | 1 | −6.45 | 4.27E-03 |
lnc-AC006156.1-11:1 | Y | −6.46 | 7.10E-04 |
lnc-AFP-1:2 | 4 | −6.56 | 5.13E-05 |
lnc-MYO16-7:1 | 13 | −6.62 | 5.66E-04 |
lnc-SLC3A2-6:1 | 11 | −6.69 | 6.61E-03 |
lnc-RABGGTB-1:6 | 1 | −6.84 | 5.72E-04 |
SNHG1:25 | 11 | −7.00 | 1.37E-02 |
lnc-AC007952.2.1-2:2 | 17 | −7.51 | 1.91E-03 |
lnc-MOS-1:2 | 8 | −7.79 | 6.47E-04 |
LINC01138:11 | 1 | −7.81 | 1.59E-04 |
MIR503HG:16 | X | −7.92 | 1.14E-03 |
lnc-APAF1-3:1 | 12 | −7.99 | 4.93E-04 |
MIR17HG:5 | 13 | −8.00 | 1.03E-03 |
MIR503HG:17 | X | −8.05 | 1.02E-03 |
MIR99AHG:50 | 21 | −8.35 | 1.50E-04 |
MIR99AHG:51 | 21 | −8.35 | 1.47E-04 |
MIR99AHG:42 | 21 | −8.35 | 1.54E-04 |
MIR99AHG:63 | 21 | −8.37 | 1.50E-04 |
lnc-SPG7-2:3 | 16 | −8.44 | 4.74E-04 |
lnc-ERAL1-1:1 | 17 | −10.17 | 2.29E-03 |
lnc-SNAPC5-4:1 | 15 | −10.33 | 3.18E-04 |
lnc-SNAPC5-4:2 | 15 | −10.49 | 2.79E-04 |
SNHG1:1 | 11 | −10.64 | 6.00E-04 |
lnc-SNURF-1:2 | 15 | −10.67 | 1.22E-02 |
SNHG1:12 | 11 | −10.79 | 1.50E-02 |
lnc-AFP-2:1 | 4 | −11.47 | 1.18E-05 |
SNHG1:59 | 11 | −13.06 | 7.36E-04 |
LRRC75A-AS1:49 | 17 | −14.14 | 4.71E-04 |
lnc-RPL17-2:4 | 18 | −14.76 | 2.66E-04 |
LINC00910:1 | 17 | −14.92 | 1.14E-03 |
LINC00910:16 | 17 | −15.01 | 1.14E-03 |
lnc-VSTM5-1:7 | 11 | −17.05 | 3.53E-04 |
LRRC75A-AS1:41 | 17 | −17.68 | 7.08E-04 |
lnc-MINA-3:4 | 3 | −19.80 | 1.50E-04 |
lnc-SNURF-1:92 | 15 | −20.18 | 6.06E-05 |
lnc-SNURF-1:95 | 15 | −20.18 | 6.18E-05 |
lnc-TPTE-3:5 | 21 | −20.61 | 1.72E-03 |
GAS5:43 | 1 | −24.86 | 1.26E-05 |
lnc-ARHGEF6-4:1 | X | −28.38 | 1.37E-06 |
LRRC75A-AS1:36 | 17 | −31.63 | 4.59E-05 |
lnc-NEDD4L-1:6 | 18 | −32.06 | 1.18E-05 |
lnc-CCNB1IP1-1:2 | 14 | −34.31 | 2.78E-03 |
GAS5:41 | 1 | −43.46 | 1.41E-03 |
lnc-TMEM132C-11:1 | 12 | −67.46 | 6.92E-04 |
SNHG6:15 | 8 | −103.09 | 7.10E-04 |
lnc-HSD17B10-3:1 | X | −146.51 | 2.70E-04 |
lnc-AC022098.1-1:10 | 19 | −576.95 | 3.27E-05 |
SNHG1:60 | 11 | −693.84 | 4.85E-06 |
GAS5:7 | 1 | −814.77 | 1.19E-05 |
GAS5:72 | 1 | −814.77 | 1.19E-05 |
LINC01021:16 | 5 | −1317.35 | 9.16E-06 |
lnc-MBNL2-3:1 | 13 | −4157.50 | 9.10E-07 |
Table 13.
lncRNA ID | Chromosome | Fold change | FDR |
---|---|---|---|
lnc-GCNT1-4:6 | 9 | 306.64 | 2.76E-08 |
lnc-GCNT1-4:5 | 9 | 305.75 | 2.69E-08 |
lnc-GCNT1-4:2 | 9 | 302.98 | 4.40E-08 |
lnc-GCNT1-4:3 | 9 | 301.19 | 4.40E-08 |
lnc-GCNT1-4:4 | 9 | 295.48 | 4.40E-08 |
lnc-UBC-3:1 | 12 | 292.71 | 1.48E-05 |
lnc-TRIM27-18:1 | 6 | 238.48 | 1.25E-03 |
LINC00273:8 | 16 | 33.66 | 2.40E-02 |
lnc-FNBP1L-2:1 | 1 | 17.70 | 1.66E-02 |
lnc-GNGT2-1:2 | 17 | 16.60 | 6.70E-05 |
lnc-SDHC-3:1 | 1 | 15.91 | 4.38E-03 |
lnc-PRRC2C-5:1 | 1 | 13.19 | 3.82E-05 |
lnc-TRIM7-2:5 | 5 | 13.02 | 1.95E-04 |
lnc-OR2V2-3:1 | 5 | 12.02 | 2.11E-02 |
lnc-ZNF391-5:2 | 6 | 11.70 | 7.69E-03 |
lnc-IL17RB-3:1 | 3 | 8.65 | 2.54E-02 |
LIMD1-AS1:6 | 3 | 7.10 | 1.81E-03 |
MIR22HG:47 | 17 | 5.12 | 6.22E-05 |
MIR22HG:24 | 17 | 5.12 | 6.10E-05 |
MIR22HG:18 | 17 | 5.08 | 6.47E-05 |
MIR22HG:35 | 17 | 5.08 | 6.47E-05 |
lnc-ZNF133-3:1 | 20 | 4.65 | 8.10E-03 |
lnc-AL669831.1-11:4 | 1 | 4.19 | 2.94E-03 |
lnc-SAG-4:1 | 2 | 3.83 | 2.18E-03 |
lnc-RRBP1-3:1 | 20 | −1.51 | 4.91E-02 |
lnc-REG3G-6:1 | 2 | −1.75 | 3.84E-02 |
lnc-RP4-695O20__B.10.1-3:10 | 22 | −1.93 | 4.56E-02 |
lnc-RP4-695O20__B.10.1-3:9 | 22 | −1.93 | 4.60E-02 |
lnc-RP4-695O20__B.10.1-3:12 | 22 | −1.93 | 4.55E-02 |
lnc-MON2-2:8 | 12 | −1.97 | 4.43E-02 |
lnc-MON2-2:10 | 12 | −1.97 | 4.31E-02 |
lnc-MON2-2:2 | 12 | −1.98 | 4.33E-02 |
lnc-HNRNPA2B1-10:4 | 7 | −2.04 | 4.08E-02 |
lnc-IRS4-2:1 | X | −2.04 | 1.37E-02 |
MIR210HG:7 | 11 | −2.05 | 3.49E-02 |
SNHG16:42 | 17 | −2.14 | 9.50E-03 |
LINC00273:11 | 16 | −2.24 | 1.39E-02 |
lnc-SLC25A30-3:1 | 13 | −2.28 | 4.56E-02 |
lnc-NEMF-1:4 | 14 | −2.32 | 3.84E-02 |
lnc-FPR2-1:35 | 19 | −2.67 | 2.60E-02 |
DNM3OS:3 | 1 | −2.68 | 1.35E-02 |
lnc-AL031590.1-1:2 | 22 | −2.78 | 1.45E-03 |
lnc-C19orf57-6:5 | 19 | −2.88 | 1.50E-02 |
lnc-TPTE-3:4 | 21 | −2.91 | 2.61E-04 |
lnc-CUL1-5:1 | 7 | −2.97 | 6.01E-03 |
lnc-HARS-1:1 | 5 | −3.04 | 1.10E-02 |
lnc-AL669831.1-14:1 | 1 | −3.06 | 1.88E-03 |
lnc-C9orf100-1:1 | 9 | −3.09 | 9.39E-04 |
lnc-AL669831.1-12:2 | 1 | −3.20 | 1.09E-03 |
lnc-ANKRD34B-4:2 | 5 | −3.22 | 3.65E-03 |
lnc-TRIM52-2:1 | 5 | −3.26 | 1.35E-03 |
SNHG1:4 | 11 | −3.33 | 1.94E-02 |
SNHG1:44 | 11 | −3.33 | 1.94E-02 |
lnc-CFH-2:1 | 1 | −3.33 | 1.16E-02 |
lnc-FGG-2:1 | 4 | −3.34 | 1.46E-03 |
lnc-ZNF169-7:2 | 9 | −3.37 | 2.81E-02 |
SNHG22:3 | 18 | −3.38 | 1.46E-03 |
lnc-GMEB1-1:5 | 1 | −3.40 | 1.23E-02 |
lnc-SNAPC5-4:3 | 15 | −3.46 | 7.41E-03 |
lnc-RPL13A-1:5 | 19 | −3.51 | 4.33E-04 |
lnc-TMC2-1:1 | 20 | −3.58 | 1.49E-03 |
lnc-SNURF-1:73 | 15 | −3.82 | 4.76E-03 |
SNHG5:5 | 6 | −3.92 | 1.37E-03 |
SNHG5:47 | 6 | −3.92 | 1.37E-03 |
lnc-LRR1-1:1 | 14 | −3.96 | 4.88E-03 |
lnc-LRR1-1:4 | 14 | −4.00 | 4.66E-03 |
MIR17HG:6 | 13 | −4.09 | 3.17E-03 |
UBA6-AS1:26 | 4 | −4.13 | 3.02E-04 |
lnc-DAO-3:1 | 12 | −4.13 | 1.95E-04 |
MIR99AHG:42 | 21 | −4.40 | 3.20E-04 |
MIR99AHG:63 | 21 | −4.41 | 3.05E-04 |
MIR99AHG:51 | 21 | −4.41 | 2.99E-04 |
MIR99AHG:50 | 21 | −4.41 | 3.07E-04 |
lnc-AK3-1:1 | 9 | −4.52 | 1.49E-02 |
lnc-MINA-3:5 | 3 | −4.58 | 4.83E-02 |
lnc-AFP-1:2 | 4 | −4.61 | 1.20E-04 |
lnc-AFP-3:1 | 4 | −4.73 | 6.18E-05 |
GAS5:68 | 1 | −4.82 | 8.89E-04 |
lnc-SYT10-3:5 | 12 | −4.83 | 2.39E-04 |
lnc-AC106017.1.1-2:2 | 17 | −5.05 | 1.62E-04 |
ZFAS1:23 | 20 | −5.13 | 4.77E-04 |
lnc-SLC15A4-24:1 | 12 | −5.27 | 9.67E-05 |
lnc-VSTM5-1:10 | 11 | −5.28 | 4.80E-03 |
GAS5:16 | 1 | −5.32 | 8.40E-03 |
lnc-SPG7-2:3 | 16 | −5.39 | 2.51E-03 |
MIR503HG:16 | X | −5.40 | 3.87E-03 |
lnc-TRIM59-2:1 | 3 | −5.45 | 6.70E-05 |
SNHG8:14 | 4 | −5.54 | 4.91E-02 |
MIR503HG:17 | X | −5.57 | 3.20E-03 |
lnc-TSPY10-14:1 | Y | −5.60 | 1.12E-05 |
lnc-TTLL10-3:9 | 1 | −5.63 | 5.54E-03 |
lnc-SLC3A2-6:1 | 11 | −5.63 | 9.50E-03 |
LINC00273:1 | 16 | −5.75 | 3.85E-05 |
lnc-SNURF-1:2 | 15 | −5.95 | 2.64E-03 |
lnc-TPTE-3:5 | 21 | −5.99 | 3.08E-02 |
lnc-GPR39-10:3 | 2 | −6.00 | 8.60E-06 |
lnc-KIF2C-2:1 | 1 | −6.04 | 2.16E-04 |
lnc-RABGGTB-1:6 | 1 | −6.38 | 4.67E-04 |
lnc-AFP-2:1 | 4 | −6.72 | 3.18E-05 |
SNHG1:12 | 11 | −6.73 | 9.93E-03 |
SNHG19:3 | 16 | −6.74 | 1.06E-05 |
lnc-DNAJC12-1:1 | 10 | −6.82 | 1.71E-02 |
lnc-GPR39-7:1 | 2 | −6.83 | 4.56E-06 |
lnc-COL4A5-3:1 | X | −6.87 | 2.97E-04 |
lnc-ZBTB37-2:1 | 1 | −7.10 | 3.12E-03 |
lnc-CTD-2144E22.5.1-19:1 | 16 | −7.13 | 5.07E-04 |
lnc-SERHL2-4:4 | 22 | −7.33 | 6.07E-03 |
lnc-SERHL2-4:2 | 22 | −7.33 | 6.07E-03 |
lnc-KLK1-2:3 | 19 | −7.62 | 3.05E-04 |
lnc-APAF1-3:1 | 12 | −7.94 | 3.07E-04 |
lnc-AUTS2-6:1 | 7 | −8.38 | 1.07E-06 |
lnc-AC007952.2.1-2:2 | 17 | −8.55 | 1.44E-02 |
lnc-GPR39-10:2 | 2 | −8.80 | 1.53E-07 |
lnc-CRKL-2:1 | 22 | −8.88 | 1.21E-04 |
lnc-HAUS5-3:2 | 19 | −9.02 | 8.35E-05 |
lnc-HAUS5-3:1 | 19 | −9.03 | 8.47E-05 |
lnc-MOS-1:2 | 8 | −9.24 | 2.95E-04 |
LRRC75A-AS1:49 | 17 | −9.48 | 1.37E-03 |
lnc-MYO16-7:1 | 13 | −9.67 | 4.56E-06 |
lnc-SNURF-1:92 | 15 | −10.05 | 2.32E-04 |
lnc-AUTS2-6:2 | 7 | −10.05 | 3.06E-06 |
lnc-TPTE-3:9 | 21 | −10.19 | 8.25E-03 |
lnc-AC006156.1-11:1 | Y | −10.27 | 6.52E-05 |
lnc-SNURF-1:95 | 15 | −10.49 | 2.06E-04 |
lnc-SNAPC5-4:2 | 15 | −10.58 | 2.81E-04 |
lnc-SNAPC5-4:1 | 15 | −10.70 | 2.78E-04 |
MIR17HG:5 | 13 | −10.86 | 5.80E-04 |
lnc-GCNT1-4:1 | 9 | −11.55 | 1.95E-04 |
lnc-RPL17-2:4 | 18 | −13.78 | 2.45E-04 |
lnc-TMEM132C-11:1 | 12 | −14.40 | 1.56E-03 |
SNHG1:59 | 11 | −14.45 | 6.70E-05 |
SNHG1:1 | 11 | −15.41 | 6.28E-05 |
LINC00910:1 | 17 | −16.17 | 9.82E-04 |
LINC00910:16 | 17 | −16.27 | 9.82E-04 |
LINC01138:11 | 1 | −16.27 | 4.28E-07 |
lnc-NEDD4L-1:6 | 18 | −16.89 | 8.47E-05 |
lnc-VSTM5-1:7 | 11 | −19.43 | 3.30E-04 |
LRRC75A-AS1:41 | 17 | −33.16 | 6.44E-03 |
lnc-ARHGEF6-4:1 | X | −34.34 | 4.40E-08 |
lnc-MINA-3:4 | 3 | −36.74 | 2.35E-03 |
LRRC75A-AS1:36 | 17 | −41.92 | 1.37E-04 |
lnc-CCNB1IP1-1:2 | 14 | −48.86 | 2.60E-04 |
GAS5:43 | 1 | −50.97 | 1.92E-04 |
lnc-CTD-2144E22.5.1-20:1 | 16 | −89.06 | 2.07E-03 |
lnc-HSD17B10-3:1 | X | −104.76 | 7.69E-04 |
GAS5:41 | 1 | −237.50 | 6.47E-05 |
SNHG6:15 | 8 | −408.63 | 1.61E-04 |
GAS5:7 | 1 | −685.38 | 1.16E-05 |
GAS5:72 | 1 | −685.38 | 1.16E-05 |
lnc-AC022098.1-1:10 | 19 | −1602.87 | 1.29E-05 |
Differentially expressed lncRNAs in all five groups were listed in a Venn diagram (Fig. 6F), which showed, 109 lncRNAs were commonly expressed in all groups; whereas, 16 in cirrhosis, 3 in LGDN, 1 in HGDN, 39 in eHCC, and 3 in HCC were uniquely expressed (Fig. 6F). Several lncRNAs were commonly expressed between groups. Specifically, 19 in LGDN and eHCC; 10 in cirrhosis, LGDN, and eHCC; and 6 in LGDN, HGDN, eHCC, and HCC (Fig. 6F). We also organized a Circos Plot for comprehensive visualization of differentially expressed lncRNAs in the five groups with chromosome number and location (Fig. 6G). After plugging the data into Circos Plot, we found chromosomes 1, 2, 9, 13, 17, and X were the most enriched chromosomes in all five groups (Fig. 6G).
Differential Expression of circRNA in Cirrhosis, LGDN, HGDN, eHCC, and HCC Tissue Samples
We used circRNA annotation to identify differential expression in cirrhosis, LGDN, HGDN, eHCC, and HCC (Fig. 7A–E, Tables 15–19). We found 70 circRNAs in cirrhosis (24 upregulated and 46 downregulated; Fig. 7A, Table 15), 56 circRNAs in LGDN (16 upregulated and 40 downregulated; Fig. 7B, Table 16), 51 circRNAs in HGDN (14 upregulated and 37 downregulated; Fig. 7C, Table 17), 60 circRNAs in eHCC (14 upregulated and 46 downregulated; Fig. 7D, Table 18), and 70 circRNAs in HCC (26 upregulated and 44 downregulated; Fig. 7E, Table 19). The top five differentially upregulated circRNAs in cirrhosis (Table 15) were: circR-0040679 (2328-fold), circR-0015774 (1622-fold), circR-0016456 (1039-fold), circR-0015637 (810-fold), and circR-0014848 (591-fold); whereas, the top five downregulated were: circR-0035407 (258-fold), circR-0035409 (245-fold), circR-0092360 (39-fold), circR-0043980 (26-fold), and circR-0007956 (21-fold). The top five differentially upregulated circRNAs in LGDN (Table 16) were: circR-0087119 (455-fold), circR-0014848 (454-fold), circR-0015637 (369-fold), circR-0015774 (126-fold), and circR-0008347 (116-fold). circR-0006257 (48723-fold), circR-0035409 (2745-fold), circR-0034507 (791-fold), circR-0089763 (86-fold), and circR-0076872 (71-fold) were downregulated. The top five differentially upregulated circRNAs in HGDN (Table 17) were: circR-0054435 (2907-fold), circR-0015637 (454-fold), circR-0015774 (417-fold), circR-000007119 (265-fold), and circR-0040679 (211-fold); whereas the top five downregulated were: circR-0006257 (27596-fold), circR-0035409 (1234-fold), circR-0035407 (995-fold), circR-0076872 (44-fold), and circR-0092360 (28-fold). The top five differentially upregulated circRNAs in eHCC (Table 18) were: circR-0015637 (556-fold), circR-0015774 (516-fold), circR-0087119 (315-fold), circR-0040679 (258-fold), and circR-0087948 (254-fold); and circR-0006257 (19579-fold), circR-0035409 (810-fold), circR-0035407 (623-fold), circR-0076872 (47-fold), and circR-0092360 (29-fold) were downregulated. The top five differentially upregulated circRNAs in HCC (Table 19) were: circR-0021905 (800542-fold), circR-0016456 (1204-fold), circR-0015637 (608-fold), circR-0087119 (602-fold), and circR-0014848 (438-fold). The top five downregulated were: circR-0035409 (1219-fold), circR-0035407 (784-fold), circR-0076872 (98-fold), circR-0092360 (15-fold), and circR-0069970 (13-fold).
Table 15.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa_circ_0040679 | 16 | 2327.99 | 1.34E-08 |
hsa_circ_0015774 | 1 | 1621.70 | 5.47E-10 |
hsa_circ_0016456 | 1 | 1039.17 | 1.35E-07 |
hsa_circ_0015637 | 1 | 809.57 | 3.13E-11 |
hsa_circ_0014848 | 1 | 591.30 | 7.64E-07 |
hsa_circ_0054435 | 2 | 451.43 | 3.58E-08 |
hsa_circ_0087948 | 9 | 180.01 | 1.31E-14 |
hsa_circ_0087119 | 9 | 122.08 | 3.40E-04 |
hsa_circ_0019374 | 10 | 97.40 | 2.73E-06 |
hsa_circ_0012861 | 1 | 86.11 | 2.10E-06 |
hsa_circ_0008347 | 19 | 59.74 | 8.62E-05 |
hsa_circ_0069968 | 4 | 38.17 | 2.86E-06 |
hsa_circ_0069969 | 4 | 38.17 | 2.83E-06 |
hsa_circ_0079763 | 7 | 27.36 | 1.85E-02 |
hsa_circ_0006061 | 1 | 27.15 | 1.32E-08 |
hsa_circ_0069749 | 4 | 11.31 | 4.43E-04 |
hsa_circ_0009016 | 11 | 10.30 | 1.30E-06 |
hsa_circ_0043602 | 17 | 5.39 | 1.25E-02 |
hsa_circ_0043601 | 17 | 5.39 | 1.28E-02 |
hsa_circ_0043605 | 17 | 5.29 | 9.64E-03 |
hsa_circ_0043604 | 17 | 5.26 | 1.01E-02 |
hsa_circ_0043603 | 17 | 5.21 | 1.42E-02 |
hsa_circ_0034154 | 15 | 2.97 | 4.16E-02 |
hsa_circ_0004659 | 17 | 1.73 | 2.23E-02 |
hsa_circ_0034118 | 15 | −2.15 | 1.70E-02 |
hsa_circ_0034110 | 15 | −2.44 | 1.48E-02 |
hsa_circ_0055902 | 2 | −2.53 | 2.75E-03 |
hsa_circ_0034138 | 15 | −2.67 | 7.89E-03 |
hsa_circ_0022568 | 11 | −2.96 | 4.03E-03 |
hsa_circ_0000146 | 1 | −2.97 | 2.14E-02 |
hsa_circ_0031772 | 14 | −3.14 | 5.91E-04 |
hsa_circ_0008733 | 1 | −3.20 | 6.59E-03 |
hsa_circ_0002978 | 1 | −3.21 | 6.16E-03 |
hsa_circ_0004784 | 1 | −3.22 | 6.16E-03 |
hsa_circ_0006643 | 1 | −3.22 | 5.89E-03 |
hsa_circ_0090906 | X | −3.30 | 1.99E-02 |
hsa_circ_0000705 | 16 | −3.55 | 2.16E-03 |
hsa_circ_0063778 | 22 | −3.75 | 2.20E-03 |
hsa_circ_0067418 | 3 | −4.22 | 3.72E-04 |
hsa_circ_0007319 | 7 | −4.88 | 3.74E-06 |
hsa_circ_0006940 | 14 | −5.24 | 7.79E-05 |
hsa_circ_0034121 | 15 | −5.28 | 2.76E-03 |
hsa_circ_0092282 | 1 | −5.34 | 7.09E-05 |
hsa_circ_0081371 | 7 | −5.37 | 1.16E-05 |
hsa_circ_0069967 | 4 | −5.57 | 2.23E-05 |
hsa_circ_0034117 | 15 | −5.66 | 2.58E-03 |
hsa_circ_0010166 | 1 | −6.21 | 2.36E-04 |
hsa_circ_0040412 | 16 | −6.75 | 3.24E-06 |
hsa_circ_0001853 | 9 | −6.84 | 1.21E-05 |
hsa_circ_0092300 | 2 | −7.54 | 8.76E-05 |
hsa_circ_0092280 | 1 | −7.97 | 2.15E-04 |
hsa_circ_0039972 | 16 | −8.61 | 8.88E-06 |
hsa_circ_0004287 | 11 | −9.77 | 1.35E-07 |
hsa_circ_0007636 | 1 | −10.13 | 1.39E-03 |
hsa_circ_0008442 | 1 | −10.29 | 9.87E-04 |
hsa_circ_0007702 | 2 | −10.60 | 3.04E-06 |
hsa_circ_0052884 | 2 | −10.78 | 1.62E-06 |
hsa_circ_0022547 | 11 | −11.22 | 5.22E-05 |
hsa_circ_0092275 | 1 | −11.82 | 2.50E-05 |
hsa_circ_0069970 | 4 | −12.02 | 8.64E-07 |
hsa_circ_0092342 | 11 | −14.00 | 2.17E-03 |
hsa_circ_0076872 | 6 | −16.04 | 8.64E-07 |
hsa_circ_0024018 | 11 | −17.54 | 1.58E-03 |
hsa_circ_0024019 | 11 | −17.91 | 5.58E-04 |
hsa_circ_0071320 | 4 | −19.54 | 7.31E-07 |
hsa_circ_0007956 | 18 | −20.82 | 1.47E-03 |
hsa_circ_0043980 | 17 | −26.23 | 3.38E-06 |
hsa_circ_0092360 | 17 | −38.68 | 7.66E-05 |
hsa_circ_0035409 | 15 | −248.93 | 8.64E-07 |
hsa_circ_0035407 | 15 | −258.02 | 6.97E-07 |
Table 19.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa_circ_0021905 | 11 | 800542.00 | 5.29E-31 |
hsa_circ_0016456 | 1 | 1204.47 | 4.52E-10 |
hsa_circ_0015637 | 1 | 607.83 | 1.37E-18 |
hsa_circ_0087119 | 9 | 602.14 | 3.06E-09 |
hsa_circ_0014848 | 1 | 437.51 | 1.49E-09 |
hsa_circ_0015774 | 1 | 308.14 | 4.00E-11 |
hsa_circ_0040679 | 16 | 228.28 | 5.92E-12 |
hsa_circ_0087948 | 9 | 125.30 | 4.13E-16 |
hsa_circ_0008347 | 19 | 114.16 | 1.65E-14 |
hsa_circ_0019374 | 10 | 61.21 | 1.36E-04 |
hsa_circ_0012861 | 1 | 24.27 | 6.41E-11 |
hsa_circ_0043602 | 17 | 21.84 | 1.24E-05 |
hsa_circ_0043601 | 17 | 21.55 | 1.23E-05 |
hsa_circ_0043605 | 17 | 21.26 | 1.63E-06 |
hsa_circ_0043604 | 17 | 21.13 | 1.68E-06 |
hsa_circ_0043603 | 17 | 21.00 | 1.37E-05 |
hsa_circ_0006061 | 1 | 13.52 | 1.62E-09 |
hsa_circ_0002189 | 8 | 7.83 | 7.01E-07 |
hsa_circ_0009060 | 16 | 7.02 | 1.68E-05 |
hsa_circ_0034021 | 14 | 5.93 | 1.57E-02 |
hsa_circ_0005554 | 14 | 5.15 | 1.94E-02 |
hsa_circ_0009016 | 11 | 4.44 | 2.22E-07 |
hsa_circ_0051491 | 19 | 3.74 | 8.30E-05 |
hsa_circ_0064383 | 3 | 3.61 | 1.36E-04 |
hsa_circ_0016169 | 1 | 2.87 | 3.30E-02 |
hsa_circ_0004659 | 17 | 1.56 | 2.21E-02 |
hsa_circ_0089763 | M | −1.12 | 1.01E-03 |
hsa_circ_0071319 | 4 | −1.54 | 2.20E-02 |
hsa_circ_0010166 | 1 | −1.91 | 3.06E-02 |
hsa_circ_0019218 | 10 | −2.20 | 6.32E-04 |
hsa_circ_0004489 | 14 | −2.21 | 3.26E-03 |
hsa_circ_0034110 | 15 | −2.23 | 1.15E-02 |
hsa_circ_0000705 | 16 | −2.38 | 3.34E-05 |
hsa_circ_0055902 | 2 | −2.39 | 8.97E-05 |
hsa_circ_0001853 | 9 | −2.41 | 1.96E-03 |
hsa_circ_0090906 | X | −2.47 | 1.19E-02 |
hsa_circ_0063778 | 22 | −2.50 | 6.21E-03 |
hsa_circ_0022568 | 11 | −2.52 | 1.42E-03 |
hsa_circ_0034138 | 15 | −2.54 | 6.47E-03 |
hsa_circ_0092280 | 1 | −2.69 | 1.19E-02 |
hsa_circ_0002571 | 14 | −2.76 | 1.58E-03 |
hsa_circ_0034121 | 15 | −2.97 | 8.08E-03 |
hsa_circ_0034117 | 15 | −2.98 | 1.75E-02 |
hsa_circ_0092342 | 11 | −2.99 | 1.47E-03 |
hsa_circ_0022547 | 11 | −3.30 | 5.06E-03 |
hsa_circ_0067418 | 3 | −3.70 | 3.66E-05 |
hsa_circ_0040412 | 16 | −3.82 | 4.65E-05 |
hsa_circ_0092300 | 2 | −3.82 | 1.70E-05 |
hsa_circ_0003812 | 11 | −3.90 | 1.13E-03 |
hsa_circ_0004287 | 11 | −4.24 | 1.59E-07 |
hsa_circ_0081371 | 7 | −4.36 | 6.84E-07 |
hsa_circ_0092275 | 1 | −4.65 | 2.76E-04 |
hsa_circ_0052884 | 2 | −4.89 | 2.41E-06 |
hsa_circ_0092282 | 1 | −5.04 | 5.12E-09 |
hsa_circ_0052882 | 2 | −5.37 | 1.52E-07 |
hsa_circ_0034118 | 15 | −6.34 | 5.39E-04 |
hsa_circ_0071323 | 4 | −6.56 | 1.50E-05 |
hsa_circ_0007319 | 7 | −6.85 | 1.94E-11 |
hsa_circ_0007956 | 18 | −7.25 | 3.56E-06 |
hsa_circ_0024019 | 11 | −7.44 | 2.24E-06 |
hsa_circ_0024018 | 11 | −7.58 | 1.65E-06 |
hsa_circ_0071320 | 4 | −7.99 | 2.41E-06 |
hsa_circ_0039972 | 16 | −8.42 | 4.52E-10 |
hsa_circ_0069967 | 4 | −11.02 | 4.61E-11 |
hsa_circ_0043980 | 17 | −11.70 | 1.15E-05 |
hsa_circ_0069970 | 4 | −13.17 | 1.15E-09 |
hsa_circ_0092360 | 17 | −15.18 | 2.95E-08 |
hsa_circ_0076872 | 6 | −97.52 | 8.42E-19 |
hsa_circ_0035407 | 15 | −783.68 | 3.39E-11 |
hsa_circ_0035409 | 15 | −1219.10 | 3.39E-11 |
Table 16.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa_circ_0087119 | 9 | 454.61 | 2.78E-05 |
hsa_circ_0014848 | 1 | 454.34 | 1.95E-05 |
hsa_circ_0015637 | 1 | 368.71 | 7.33E-11 |
hsa_circ_0015774 | 1 | 126.00 | 1.72E-08 |
hsa_circ_0008347 | 19 | 116.32 | 2.00E-09 |
hsa_circ_0040679 | 16 | 111.54 | 1.93E-09 |
hsa_circ_0087948 | 9 | 60.83 | 7.33E-11 |
hsa_circ_0043602 | 17 | 19.26 | 6.33E-04 |
hsa_circ_0043601 | 17 | 19.22 | 6.33E-04 |
hsa_circ_0043605 | 17 | 18.79 | 5.24E-04 |
hsa_circ_0043603 | 17 | 18.67 | 5.99E-04 |
hsa_circ_0043604 | 17 | 18.63 | 5.37E-04 |
hsa_circ_0006061 | 1 | 10.72 | 2.54E-06 |
hsa_circ_0009016 | 11 | 5.35 | 3.47E-04 |
hsa_circ_0051491 | 19 | 4.94 | 2.45E-03 |
hsa_circ_0064383 | 3 | 2.35 | 3.79E-02 |
hsa_circ_0063778 | 22 | −1.73 | 4.65E-02 |
hsa_circ_0006940 | 14 | −1.82 | 4.56E-02 |
hsa_circ_0031772 | 14 | −1.86 | 1.94E-02 |
hsa_circ_0055902 | 2 | −1.97 | 1.26E-02 |
hsa_circ_0000705 | 16 | −2.14 | 4.01E-03 |
hsa_circ_0004489 | 14 | −2.29 | 1.54E-02 |
hsa_circ_0001853 | 9 | −2.30 | 1.05E-02 |
hsa_circ_0010166 | 1 | −2.45 | 3.93E-02 |
hsa_circ_0034110 | 15 | −2.53 | 2.13E-02 |
hsa_circ_0002571 | 14 | −3.01 | 2.14E-03 |
hsa_circ_0052884 | 2 | −3.15 | 4.52E-03 |
hsa_circ_0040412 | 16 | −3.37 | 1.25E-03 |
hsa_circ_0022568 | 11 | −3.37 | 8.86E-04 |
hsa_circ_0034117 | 15 | −3.70 | 3.26E-02 |
hsa_circ_0034138 | 15 | −3.74 | 1.60E-03 |
hsa_circ_0022547 | 11 | −3.85 | 1.41E-02 |
hsa_circ_0071320 | 4 | −4.26 | 1.78E-03 |
hsa_circ_0092342 | 11 | −4.49 | 1.37E-03 |
hsa_circ_0092282 | 1 | −4.70 | 4.02E-05 |
hsa_circ_0069967 | 4 | −4.73 | 6.48E-05 |
hsa_circ_0092300 | 2 | −4.87 | 1.46E-04 |
hsa_circ_0081371 | 7 | −4.92 | 1.09E-04 |
hsa_circ_0034118 | 15 | −5.09 | 1.31E-02 |
hsa_circ_0092275 | 1 | −5.35 | 1.93E-03 |
hsa_circ_0069970 | 4 | −5.44 | 1.47E-04 |
hsa_circ_0092280 | 1 | −5.76 | 4.92E-04 |
hsa_circ_0034121 | 15 | −6.03 | 1.35E-02 |
hsa_circ_0004287 | 11 | −6.07 | 8.33E-05 |
hsa_circ_0007319 | 7 | −8.02 | 1.86E-08 |
hsa_circ_0043980 | 17 | −8.35 | 1.31E-03 |
hsa_circ_0024018 | 11 | −8.97 | 3.79E-05 |
hsa_circ_0024019 | 11 | −9.04 | 3.49E-05 |
hsa_circ_0039972 | 16 | −9.50 | 1.79E-05 |
hsa_circ_0007956 | 18 | −10.74 | 1.52E-05 |
hsa_circ_0092360 | 17 | −25.62 | 1.66E-07 |
hsa_circ_0076872 | 6 | −71.14 | 2.26E-10 |
hsa_circ_0089763 | M | −86.14 | 9.20E-06 |
hsa_circ_0035407 | 15 | −790.56 | 6.21E-07 |
hsa_circ_0035409 | 15 | −2745.28 | 5.53E-08 |
hsa_circ_0006257 | 12 | −48722.51 | 2.34E-09 |
Table 17.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa_circ_0054435 | 2 | 2907.43 | 3.25E-03 |
hsa_circ_0015637 | 1 | 454.29 | 1.93E-07 |
hsa_circ_0015774 | 1 | 416.69 | 1.82E-05 |
hsa_circ_0087119 | 9 | 265.25 | 7.85E-04 |
hsa_circ_0040679 | 16 | 211.05 | 1.61E-06 |
hsa_circ_0087948 | 9 | 90.25 | 4.85E-07 |
hsa_circ_0008347 | 19 | 83.53 | 4.47E-06 |
hsa_circ_0006061 | 1 | 13.47 | 1.72E-03 |
hsa_circ_0009016 | 11 | 7.07 | 4.46E-03 |
hsa_circ_0043602 | 17 | 6.37 | 3.17E-02 |
hsa_circ_0043601 | 17 | 6.36 | 3.58E-02 |
hsa_circ_0043605 | 17 | 6.16 | 2.94E-02 |
hsa_circ_0043603 | 17 | 6.16 | 3.60E-02 |
hsa_circ_0051491 | 19 | 3.45 | 1.84E-02 |
hsa_circ_0063778 | 22 | −1.93 | 4.40E-02 |
hsa_circ_0089763 | M | −1.98 | 2.43E-02 |
hsa_circ_0006940 | 14 | −2.35 | 2.96E-02 |
hsa_circ_0004489 | 14 | −2.45 | 1.84E-02 |
hsa_circ_0031772 | 14 | −2.48 | 1.08E-02 |
hsa_circ_0055902 | 2 | −3.03 | 1.46E-04 |
hsa_circ_0022568 | 11 | −3.29 | 1.13E-02 |
hsa_circ_0071320 | 4 | −3.43 | 2.60E-03 |
hsa_circ_0002571 | 14 | −3.67 | 2.20E-03 |
hsa_circ_0040412 | 16 | −4.35 | 7.55E-05 |
hsa_circ_0052884 | 2 | −4.42 | 8.04E-03 |
hsa_circ_0008442 | 1 | −4.71 | 4.12E-02 |
hsa_circ_0007636 | 1 | −4.77 | 3.48E-02 |
hsa_circ_0069967 | 4 | −5.12 | 1.01E-04 |
hsa_circ_0022547 | 11 | −5.64 | 1.08E-02 |
hsa_circ_0069970 | 4 | −5.81 | 6.97E-05 |
hsa_circ_0034138 | 15 | −5.91 | 4.11E-04 |
hsa_circ_0092300 | 2 | −6.18 | 4.22E-04 |
hsa_circ_0092342 | 11 | −6.77 | 4.34E-02 |
hsa_circ_0001853 | 9 | −7.36 | 5.60E-05 |
hsa_circ_0092280 | 1 | −7.72 | 2.17E-03 |
hsa_circ_0004287 | 11 | −8.52 | 4.90E-05 |
hsa_circ_0092282 | 1 | −8.66 | 1.84E-05 |
hsa_circ_0092275 | 1 | −9.62 | 4.47E-03 |
hsa_circ_0007319 | 7 | −9.86 | 4.85E-07 |
hsa_circ_0039972 | 16 | −10.98 | 3.05E-05 |
hsa_circ_0007956 | 18 | −12.27 | 3.78E-04 |
hsa_circ_0034121 | 15 | −12.37 | 2.80E-03 |
hsa_circ_0024019 | 11 | −12.37 | 1.24E-04 |
hsa_circ_0024018 | 11 | −12.67 | 1.11E-04 |
hsa_circ_0034118 | 15 | −14.24 | 2.70E-04 |
hsa_circ_0043980 | 17 | −16.26 | 1.07E-03 |
hsa_circ_0092360 | 17 | −27.80 | 9.02E-03 |
hsa_circ_0076872 | 6 | −43.61 | 4.85E-07 |
hsa_circ_0035407 | 15 | −994.94 | 7.76E-11 |
hsa_circ_0035409 | 15 | −1234.90 | 1.96E-07 |
hsa_circ_0006257 | 12 | −27596.01 | 4.85E-07 |
Table 18.
Feature ID | Chromosome | Fold change | FDR |
---|---|---|---|
hsa_circ_0015637 | 1 | 556.31 | 8.94E-09 |
hsa_circ_0015774 | 1 | 515.70 | 2.74E-07 |
hsa_circ_0087119 | 9 | 314.69 | 2.71E-03 |
hsa_circ_0040679 | 16 | 258.13 | 4.88E-08 |
hsa_circ_0087948 | 9 | 253.91 | 3.36E-07 |
hsa_circ_0008347 | 19 | 88.59 | 2.08E-05 |
hsa_circ_0069969 | 4 | 32.75 | 4.85E-02 |
hsa_circ_0006061 | 1 | 27.89 | 1.87E-04 |
hsa_circ_0043602 | 17 | 13.55 | 5.26E-03 |
hsa_circ_0043601 | 17 | 13.49 | 5.26E-03 |
hsa_circ_0043605 | 17 | 13.24 | 4.89E-03 |
hsa_circ_0043604 | 17 | 13.09 | 4.94E-03 |
hsa_circ_0043603 | 17 | 13.05 | 5.89E-03 |
hsa_circ_0009016 | 11 | 7.27 | 1.64E-03 |
hsa_circ_0031772 | 14 | −2.24 | 1.14E-02 |
hsa_circ_0063778 | 22 | −2.37 | 9.10E-03 |
hsa_circ_0055902 | 2 | −2.48 | 1.75E-02 |
hsa_circ_0006940 | 14 | −2.49 | 1.38E-02 |
hsa_circ_0004489 | 14 | −2.60 | 1.38E-02 |
hsa_circ_0089763 | M | −2.96 | 1.21E-03 |
hsa_circ_0000705 | 16 | −2.97 | 4.25E-03 |
hsa_circ_0002978 | 1 | −3.04 | 2.56E-02 |
hsa_circ_0008733 | 1 | −3.04 | 2.72E-02 |
hsa_circ_0006643 | 1 | −3.04 | 2.39E-02 |
hsa_circ_0004784 | 1 | −3.05 | 2.52E-02 |
hsa_circ_0081371 | 7 | −3.17 | 5.16E-03 |
hsa_circ_0052884 | 2 | −3.39 | 1.91E-03 |
hsa_circ_0002571 | 14 | −3.50 | 4.16E-03 |
hsa_circ_0001853 | 9 | −3.68 | 2.89E-03 |
hsa_circ_0090906 | X | −3.71 | 1.12E-02 |
hsa_circ_0034138 | 15 | −3.86 | 2.86E-03 |
hsa_circ_0034118 | 15 | −3.94 | 6.64E-03 |
hsa_circ_0022568 | 11 | −4.34 | 5.88E-03 |
hsa_circ_0004287 | 11 | −4.83 | 1.05E-03 |
hsa_circ_0010166 | 1 | −4.92 | 3.53E-03 |
hsa_circ_0092275 | 1 | −4.94 | 6.76E-03 |
hsa_circ_0040412 | 16 | −5.00 | 2.97E-04 |
hsa_circ_0008442 | 1 | −5.31 | 2.15E-02 |
hsa_circ_0007636 | 1 | −5.38 | 2.08E-02 |
hsa_circ_0092282 | 1 | −5.55 | 3.43E-04 |
hsa_circ_0069967 | 4 | −6.01 | 7.74E-05 |
hsa_circ_0092342 | 11 | −6.18 | 3.14E-02 |
hsa_circ_0007319 | 7 | −6.26 | 2.30E-06 |
hsa_circ_0092300 | 2 | −6.59 | 2.29E-03 |
hsa_circ_0034117 | 15 | −6.66 | 3.19E-03 |
hsa_circ_0022547 | 11 | −6.69 | 6.43E-03 |
hsa_circ_0092280 | 1 | −6.87 | 3.00E-03 |
hsa_circ_0071320 | 4 | −8.06 | 4.03E-04 |
hsa_circ_0034121 | 15 | −8.26 | 4.71E-03 |
hsa_circ_0069970 | 4 | −9.34 | 4.64E-05 |
hsa_circ_0039972 | 16 | −10.95 | 9.20E-05 |
hsa_circ_0024018 | 11 | −11.52 | 4.20E-04 |
hsa_circ_0024019 | 11 | −11.60 | 4.03E-04 |
hsa_circ_0007956 | 18 | −13.18 | 3.43E-04 |
hsa_circ_0043980 | 17 | −15.09 | 1.13E-03 |
hsa_circ_0092360 | 17 | −29.19 | 7.77E-05 |
hsa_circ_0076872 | 6 | −46.60 | 1.73E-07 |
hsa_circ_0035407 | 15 | −622.97 | 4.30E-05 |
hsa_circ_0035409 | 15 | −810.36 | 3.04E-05 |
hsa_circ_0006257 | 12 | −19578.54 | 1.03E-06 |
A Venn diagram (Fig. 7F) showed, 41 circRNAs commonly expressed in all groups whereas, six in cirrhosis; none in LGDN, HGDN, oreHCC; and 11 in HCC were uniquely expressed (Fig. 7F). There were several circRs commonly expressed between groups: five in cirrhosis and HCC; five in cirrhosis, LGDN, eHCC, and HCC; and three in LGDN, HGDN, eHCC, and HCC (Fig. 7F). We also prepared a Circos Plot for comprehensive visualization of differentially expressed circRNAs (Fig. 7G) which found chromosomes 1, 2, 5, 6, and 22 to be the most enriched across groups (Fig. 7G).
Differential Expression of sno/mt-RNA in Cirrhosis, LGDN, HGDN, eHCC, and HCC Tissue Samples
Small nuclear RNAs form a class of RNA molecules that localize within the nucleus of eukaryotic cells28. Their primary function is pre-mRNA processing, for which they are always associated with a set of specific proteins. These complexes are referred to as small nuclear ribonucleoproteins (snRNP). The small nucleolar RNAs (snoRNAs) are another subclass of snRNA that localize in the nucleolus and are associated with the maturation of RNA molecules through chemical modifications targeting mainly rRNAs, tRNAs, and snRNAs28. We remapped aligned reads to GenCode v26 database, which contains most of the curated small RNAs to identify differential expression in cirrhosis, LGDN, HGDN, eHCC, and HCC (Fig. 8A–E, Tables 20–24). We found 10 sno/mt-RNAs in cirrhosis (Fig. 8A, Table 20), 15 sno/mt-RNAs in LGDN (Fig. 8B and Table 21), nine sno/mt-RNAs in HGDN (Fig 8C and Table 22), six sno/mt-RNAs in eHCC (Fig. 8D and Table 23), and 16 sno/mt-RNAs in HCC (Fig. 8E and Table 24). Most of the mitochondrial RNAs were upregulated in HCC and all four snoRNAs were downregulated. All five groups had downregulated snoRD121B, whereas snoRD121A was downregulated only in HCC samples.
Table 23.
Gene name | Gene type | Chromosome | Fold change | FDR |
---|---|---|---|---|
MT-TP | Mt_tRNA | M | 31.48 | 6.80E-07 |
MT-TS1 | Mt_tRNA | M | 26.18 | 2.11E-06 |
MT-TT | Mt_tRNA | M | 13.18 | 8.81E-03 |
MT-TS2 | Mt_tRNA | M | −3.77 | 2.52E-03 |
SNORD121B | snoRNA | 9 | −10.05 | 4.43E-04 |
SNORD37 | snoRNA | 19 | −11.78 | 6.27E-05 |
Table 20.
Gene name | Gene type | Chromosome | Fold change | FDR |
---|---|---|---|---|
MT-TS1 | Mt_tRNA | M | 45.05 | 4.11E-10 |
MT-TP | Mt_tRNA | M | 38.27 | 3.33E-09 |
MT-TH | Mt_tRNA | M | −1.56 | 3.48E-02 |
MT-TI | Mt_tRNA | M | −2.05 | 4.25E-02 |
MT-TL1 | Mt_tRNA | M | −2.19 | 9.59E-03 |
MT-TK | Mt_tRNA | M | −4.03 | 9.31E-04 |
MT-TS2 | Mt_tRNA | M | −6.09 | 5.28E-05 |
SNORD115-31 | snoRNA | 15 | −9.48 | 3.45E-03 |
SNORD37 | snoRNA | 19 | −13.81 | 8.28E-06 |
SNORD121B | snoRNA | 9 | −15.21 | 6.44E-07 |
Table 24.
Gene name | Gene type | Chromosome | Fold change | FDR |
---|---|---|---|---|
MT-TP | Mt_tRNA | M | 20.68 | 6.96E-09 |
MT-TS1 | Mt_tRNA | M | 12.82 | 1.34E-06 |
MT-TT | Mt_tRNA | M | 12.23 | 3.65E-05 |
MT-TL2 | Mt_tRNA | M | 10.90 | 8.32E-05 |
MT-TQ | Mt_tRNA | M | 8.34 | 1.11E-07 |
MT-TN | Mt_tRNA | M | 7.23 | 2.23E-05 |
MT-TV | Mt_tRNA | M | 5.11 | 1.74E-02 |
MT-TM | Mt_tRNA | M | 4.95 | 1.00E-03 |
MT-TG | Mt_tRNA | M | 4.23 | 2.25E-02 |
MT-TC | Mt_tRNA | M | 4.21 | 1.76E-06 |
MT-TE | Mt_tRNA | M | 3.05 | 3.94E-04 |
MT-TS2 | Mt_tRNA | M | −3.23 | 1.50E-04 |
SNORD115-31 | snoRNA | 15 | −4.34 | 5.04E-04 |
SNORD121B | snoRNA | 9 | −6.87 | 1.24E-07 |
SNORD121A | snoRNA | 9 | −7.45 | 1.11E-07 |
SNORD37 | snoRNA | 19 | −8.32 | 1.12E-07 |
Table 21.
Gene name | Gene type | Chromosome | Fold change | FDR |
---|---|---|---|---|
MT-TP | Mt_tRNA | M | 27.11 | 5.90E-07 |
MT-TS1 | Mt_tRNA | M | 25.43 | 5.13E-06 |
MT-TT | Mt_tRNA | M | 12.34 | 7.07E-05 |
MT-TQ | Mt_tRNA | M | 11.95 | 1.47E-04 |
MT-TN | Mt_tRNA | M | 11.56 | 8.95E-04 |
MT-TL2 | Mt_tRNA | M | 10.88 | 7.37E-05 |
MT-TC | Mt_tRNA | M | 7.62 | 3.19E-03 |
MT-TG | Mt_tRNA | M | 5.24 | 1.04E-02 |
MT-TE | Mt_tRNA | M | 4.52 | 1.84E-03 |
MT-TV | Mt_tRNA | M | 4.19 | 2.14E-02 |
MT-TM | Mt_tRNA | M | 4.18 | 1.23E-02 |
MT-TS2 | Mt_tRNA | M | −3.29 | 1.60E-03 |
SNORD115-31 | snoRNA | 15 | −4.42 | 7.03E-04 |
SNORD121B | snoRNA | 9 | −8.06 | 1.65E-05 |
SNORD37 | snoRNA | 19 | −15.97 | 1.10E-07 |
Table 22.
Gene name | Gene type | Chromosome | Fold change | FDR |
---|---|---|---|---|
MT-TP | Mt_tRNA | M | 21.76 | 1.42E-05 |
MT-TS1 | Mt_tRNA | M | 19.48 | 3.85E-05 |
MT-TT | Mt_tRNA | M | 10.44 | 6.55E-05 |
MT-TQ | Mt_tRNA | M | 8.22 | 2.66E-03 |
MT-TC | Mt_tRNA | M | 2.58 | 2.29E-02 |
MT-TS2 | Mt_tRNA | M | −4.32 | 1.27E-03 |
SNORD115-31 | snoRNA | 15 | −4.75 | 4.10E-02 |
SNORD121B | snoRNA | 9 | −11.02 | 1.33E-05 |
SNORD37 | snoRNA | 19 | −17.68 | 1.44E-05 |
Differentially expressed data for all five groups is shown in a Venn diagram (Fig. 8F), that demonstrated five sno/mt-RNAs commonly expressed in all groups whereas, four in cirrhosis; none in LGDN, HGDN, or eHCC; and one in HCC uniquely expressed (Fig. 8F). There were several sno/mt-RNAs commonly expressed between groups: six in LGDN and HCC; and one in LGDN, HGDN, and HCC (Fig. 8F). We also prepared a Circos Plot for comprehensive visualization of differentially expressed sno/mt-RNAs in the five groups (Fig. 8G). Chromosomes 9, 17, and 19 were the most enriched (Fig. 8F).
Discussion
We have identified various non-coding RNAs in liver disease samples, which can be used for validation and development of novel therapeutics for HCC. miR-101 regulates proliferation, migration, and invasion in various cancers29–32; suggesting importance in the ordered transformation from normal to malignant phenotype. This was also suggested in our study as miR-101 was continually overexpressed in all disease stages when compared to normal liver tissue. miR-22 is considered to have tumor suppressor activity; however, in our study, it showed remarkable overexpression in HCC33. miR-23a has been reported to downregulate expression of interferon regulatory factor-1 in HCC34. Accordingly, it was overexpressed in the eHCC samples we analyzed. miR-7704 was found to be highly overexpressed in HCC when compared to cirrhosis (~400-fold change).
Current therapies and targeted strategies are well documented in the literature; however, more research is needed to identify crucial players in early disease development and treatment targets. Deregulation of various pathways such as p53, RAS/MAPK, PI3K/AKT/mTOR, WNT, MET, MYC, and TGF-beta are involved in oncogenesis35. Interestingly, miR-122 affects all of these pathways while also targeting CUTL1 transcriptional repression35,36, leading to apoptosis and cell cycle arrest. Accordingly, miR-122 is downregulated in more than 70% of cancers, suggesting a crucial role in oncologic transformation. miR-122 appears to act as a tumor suppressor and its downregulation in our study may be pertinent to an ordered progression from normal liver to HCC phenotype. In our analysis, miR-122 was downregulated across all disease stages in both sequenced data and clinical samples (Fig. 1H).
The Lethal-7 (Let-7) family of miRNAs is present in multiple copies in the genome and highly conserved37. These miRNAs are known to act as tumor suppressors and prevent angiogenesis. The Let-7 family has 10 members in the human genome (Let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-98, and miR-20238), which are involved in gene regulation and cell adhesion. We found, Let-7f microRNAs were strikingly downregulated in HGDN and eHCC (1 million-fold change) and Let-7g in HCC (358-fold change) with similar reports published in gastric39,40, prostate41, colon42,43, small cell lung44, thyroid45, breast46,47, and hepatocellular cancer48,49. miR-221, was found to be upregulated in HCC via in silico analysis and has multiple known pathway targets, such as p27Kip1, p53, BMF, PI3K, PTEN, and mTOR50. Vascular endothelial growth factor (VEGF) plays a major role in tumor development, and is partly regulated by miR-16. Our data correlates with recent studies that have shown miR-16 upregulation in HCC. GEMOX (Gemcitabine and oxaliplatin) is one of the chemotherapeutic options in HCC treatment, which specifically targets VEGF and miR-1651. Other available chemotherapeutic agents such as sunitibib, linifanib, brivanib, tivantibib, and everolimus target other kinases. Specifically, everolimus targets mTOR signaling and mTOR regulated miRNAs such as miR-99a-3p (upregulated), miR-99a-5p (downregulated), miR-221 (upregulated), and miR-100 (downregulated).
Most circular RNA functions are not clear. Until now, the only clear evidence is that they can serve as miRNA “sponges”52. In our study, we found altered expression of many circular RNAs, however additional validation is needed prior to assigning functionality.
Overall, 37 dysregulated sncRNAs were shared between all five phenotypic groups. miR-101, miR-22, and circR-0015774 were the top upregulated sncRNAs, whereas miR-122, piR-952, and circR-0035409 were the most frequently downregulated. 30 piRNAs, 109 lncRNAs, 41 circRNAs, and five sno/mt-RNAs were downregulated in all groups. circR-0015774, circR-0035409, MT-TS1, and MT-TP were in the top five upregulated RNAs in all groups; whereas, sno115-31 and snoRD37 were in the top five downregulated. Specific RNAs were also dysregulated in a single group. In cirrhosis, 16 miRNAs were dysregulated whereas four were dysregulated in LGDN (let-7d, miR-141, miR-181b, and miR-3120), none in HGDN, miR-150 in eHCC, and 29 in HCC. miR200b was commonly downregulated in HGDN, eHCC, and HCC (<3.5-fold). Six piRNAs were affected only in cirrhosis, seven in HGDN, and 52 in HCC. 16 lncRNAs were affected in cirrhosis, three in LGDN (lnc-C17orf51-5:1, lnc-KDM4C-18:1, and SNHG1:57), one in HGDN (lnc-REG3G-6:1), 39 in eHCC, and three in HCC (LINC01021:16, lnc-MBNL2-3:1, and SNHG1:60). Six circRNAs in cirrhosis and 11 in HCC were specifically dysregulated. Four sno/mt-RNAs were dysregulated in cirrhosis only and one in HCC (snoRD121A).
Our results summarize that multiple differentially expressed sncRNAs were identifided in concordance with disease progression, which may provide a basis for future study and clues to understanding HCC pathogenesis. Although we have a substantial sequencing dataset, we were limited in miRNA validation by a small tissue sample size. Additionally, limited data on disease etiology prevented further analysis. Nevertheless, we believe that our study uncovers the potential of data mining for sncRNA identification with regards to HCC. It is also appreciated that further research is needed to address the functional validation of sncRNA signatures and their relevance.
In summary, miR-101, miR-22, miR-122, circR-0015774, circR-0035409, MT-TS1, MT-TP, sno115-31, and snoRD37 may serve as biomarkers for liver pathogenesis, since they were differentially expressed. Each liver phenotype demonstrated a unique molecular signature. In cirrhosis, there were 16 dysregulated miRNAs, six piRNAs, 16 lncRNAs, and six circRNAs. Four miRNAs and three lncRNAs were differentially expressed in LGDN; whereas, seven piRNAs and one lncRNA were dysregulated in HGDN. The molecular signature of eHCC was altered by one miRNA and 39 lncRNAs, while HCC demonstrated changes in 29 miRNAs, 52 piRNAs, three lncRNAs, 11 circRNAs, and one sno/mt-RNA. The sncRNAs most strongly associated with cirrhosis were mir-192 (32-fold), miR 320b (14-fold), and circ-0079763 (27-fold). LGDN was most defined by changes in miR-141(626-fold) and piR-25782.5 (309-fold), while piR-25782.1 (181-fold) was expressed in HGDN. miR-150 (4-fold) was most strongly associated with eHCC, whereas, miR-142 (1-million fold), miR23a (124-fold), miR 130b (65-fold), piR-23670 (2335-fold), piR-24684 (2072-fold), circR-0021905, and snoRD121A were specifically altered in HCC. Further studies are needed to validate sncRNA functionality in liver disease prior to biomarker development.
Electronic supplementary material
Acknowledgements
We thank Gene Arrays (An entity of Vedic Research, Inc., USA) for MetaCore data analysis free of charge and Research Informatics at Penn State College of Medicine for setting up High Performance Computing facilities. Part of this work was supported by the Department of Surgery at Penn State Health Milton S Hershey Medical Center. We thank Dr. James Broach (IPM) and Ms. Molly Pells (IPM) for providing HCC and healthy liver tissue samples, Dr. Craig Praul (Director, Penn State Genomics Core Facility, University Park, PA) for NanoString Data aquisition, and Ms. Yanfen Fu (NanoString Technologies, Seattle, WA) for data analysis. In addition, Dr. Irina Elcheva for critical commentary and correction of the manuscript.
Author Contributions
S.V.K., designed the study, analyzed data and interpretation, wrote the manuscript, critical revision of the manuscript; A.N.L., Y.I.K., M.M., N.J.G., A.J.S. and D.J.R., analyzed data and revised the manuscript; All authors approved the final version.
Competing Interests
The authors declare no competing interests.
Footnotes
Electronic supplementary material
Supplementary information accompanies this paper at 10.1038/s41598-018-26360-1.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Srinivas V. Koduru, Email: skoduru@pennstatehealth.psu.edu
Dino J. Ravnic, Email: dravnic@pennstatehealth.psu.edu
References
- 1.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;67:7–30. doi: 10.3322/caac.21387. [DOI] [PubMed] [Google Scholar]
- 2.Koduru S, et al. A Comprehensive NGS Data Analysis of Differentially Regulated miRNAs, piRNAs, lncRNAs and sn/snoRNAs in Triple NegativeBreast Cancer. Journal of Cancer. 2017;8:578–596. doi: 10.7150/jca.17633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Eddy SR, Non-coding RNA. genes and the modern RNA world. Nat Rev Genet. 2001;2:919–929. doi: 10.1038/35103511. [DOI] [PubMed] [Google Scholar]
- 4.Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854. doi: 10.1016/0092-8674(93)90529-Y. [DOI] [PubMed] [Google Scholar]
- 5.Sai Lakshmi S, Agrawal S. piRNABank: a web resource on classified and clustered Piwi-interacting RNAs. Nucleic Acids Research. 2008;36:D173–D177. doi: 10.1093/nar/gkm696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Cao J. The functional role of long non-coding RNAs and epigenetics. Biological Procedures Online. 2014;16:11. doi: 10.1186/1480-9222-16-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Scott MS, et al. Human box C/D snoRNA processing conservation across multiple cell types. Nucleic Acids Research. 2011;40:3676–3688. doi: 10.1093/nar/gkr1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Thomson T, Lin H. The Biogenesis and Function PIWI Proteins and piRNAs: Progress and Prospect. Annual review of cell and developmental biology. 2009;25:355–376. doi: 10.1146/annurev.cellbio.24.110707.175327. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Derrien T, et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 2012;22:1775–1789. doi: 10.1101/gr.132159.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Nigro JM, et al. Scrambled exons. Cell. 1991;64:607–613. doi: 10.1016/0092-8674(91)90244-S. [DOI] [PubMed] [Google Scholar]
- 11.Jakobi T, Czaja-Hasse LF, Reinhardt R, Dieterich C. Profiling and Validation of the Circular RNA Repertoire in Adult Murine Hearts. Genomics, Proteomics & Bioinformatics. 2016;14:216–223. doi: 10.1016/j.gpb.2016.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Gao Y, Wang J, Zhao F. CIRI: an efficient and unbiased algorithm for de novo circular RNA identification. Genome Biology. 2015;16:4. doi: 10.1186/s13059-014-0571-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Scott MS, Ono M. From snoRNA to miRNA: Dual function regulatory non-coding RNAs. Biochimie. 2011;93:1987–1992. doi: 10.1016/j.biochi.2011.05.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Wojcicka A, et al. Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. The International Journal of Biochemistry & Cell Biology. 2014;53:208–217. doi: 10.1016/j.biocel.2014.05.020. [DOI] [PubMed] [Google Scholar]
- 15.Leinonen R, Sugawara H, Shumway M. & on behalf of the International Nucleotide Sequence Database, C. The Sequence Read Archive. Nucleic Acids Research. 2011;39:D19–D21. doi: 10.1093/nar/gkq1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Koduru S, Tiwari A, Hazard S, Mahajan M, Ravnic D. Exploration of small RNA-seq data for small non-coding RNAs in Human Colorectal Cancer. Journal of Genomics. 2017;5:16–31. doi: 10.7150/jgen.18856. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Research. 2014;42:D68–D73. doi: 10.1093/nar/gkt1181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Zhang P, et al. piRBase: a web resource assisting piRNA functional study. Database. 2014;2014:bau110. doi: 10.1093/database/bau110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Volders P-J, et al. An update on LNCipedia: a database for annotated human lncRNA sequences. Nucleic Acids Research. 2015;43:D174–D180. doi: 10.1093/nar/gku1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Glažar, P., Papavasileiou, P. & Rajewsky, N. circBase: a database for circular RNAs. RNA, 10.1261/rna.043687.113 (2014). [DOI] [PMC free article] [PubMed]
- 21.Harrow J, et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Research. 2012;22:1760–1774. doi: 10.1101/gr.135350.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Firmino N, et al. HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer. Oral Oncol. 2016;55:43–48. doi: 10.1016/j.oraloncology.2016.01.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Krzywinski M, et al. Circos: An information aesthetic for comparative genomics. Genome Research. 2009;19:1639–1645. doi: 10.1101/gr.092759.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Merino MJ, Gil S, Macias CG, Lara K. The Unknown microRNA Expression of Male Breast Cancer. Similarities and Differences with Female Ductal Carcinoma. Their Role as Tumor Biomarker. Journal of Cancer. 2018;9:450–459. doi: 10.7150/jca.23151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Pathan M, et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool. PROTEOMICS. 2015;15:2597–2601. doi: 10.1002/pmic.201400515. [DOI] [PubMed] [Google Scholar]
- 26.Pathan M, et al. A novel community driven software for functional enrichment analysis of extracellular vesicles data. Journal of Extracellular Vesicles. 2017;6:1321455. doi: 10.1080/20013078.2017.1321455. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Asgharpour A, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal of hepatology. 2016;65:579–588. doi: 10.1016/j.jhep.2016.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Morceau F, Chateauvieux S, Gaigneaux A, Dicato M, Diederich M. Long and Short Non-Coding RNAs as Regulators of Hematopoietic Differentiation. International Journal of Molecular Sciences. 2013;14:14744–14770. doi: 10.3390/ijms140714744. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Deng G, et al. MicroRNA-101 inhibits the migration and invasion of intrahepatic cholangiocarcinoma cells via direct suppression of vascular endothelial growth factor-C. Molecular medicine reports. 2015;12:7079–7085. doi: 10.3892/mmr.2015.4239. [DOI] [PubMed] [Google Scholar]
- 30.Guan H, et al. MicroRNA-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancer. International journal of molecular medicine. 2016;37:1643–1651. doi: 10.3892/ijmm.2016.2557. [DOI] [PubMed] [Google Scholar]
- 31.Long Y, et al. MicroRNA-101 inhibits the proliferation and invasion of bladder cancer cells via targeting c-FOS. Molecular medicine reports. 2016;14:2651–2656. doi: 10.3892/mmr.2016.5534. [DOI] [PubMed] [Google Scholar]
- 32.Li G, Yang F, Gu S, Li Z, Xue M. MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C. Molecular medicine reports. 2016;13:572–578. doi: 10.3892/mmr.2015.4560. [DOI] [PubMed] [Google Scholar]
- 33.Wang J, et al. Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review) International Journal of Oncology. 2017;50:345–355. doi: 10.3892/ijo.2016.3811. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Yan Y, Liang Z, Du Q, Yang M, Geller DA. MicroRNA-23a downregulates the expression of interferon regulatory factor-1 in hepatocellular carcinoma cells. Oncology Reports. 2016;36:633–640. doi: 10.3892/or.2016.4864. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. OncoTargets and therapy. 2013;6:1167–1178. doi: 10.2147/OTT.S36161. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Xu H, et al. Liver-enriched transcription factors regulate MicroRNA-122 that targets CUTL1 during liver development. Hepatology. 2010;52:1431–1442. doi: 10.1002/hep.23818. [DOI] [PubMed] [Google Scholar]
- 37.Roush S, Slack FJ. The let-7 family of microRNAs. Trends in Cell Biology. 2008;18:505–516. doi: 10.1016/j.tcb.2008.07.007. [DOI] [PubMed] [Google Scholar]
- 38.Thammaiah CK, Jayaram S. Role of let-7 family microRNA in breast cancer. Non-coding RNA Research. 2016;1:77–82. doi: 10.1016/j.ncrna.2016.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Kang W, et al. let-7b/g silencing activates AKT signaling to promote gastric carcinogenesis. Journal of Translational Medicine. 2014;12:281. doi: 10.1186/s12967-014-0281-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Hu H, Zhao X, Jin Z, Hou M. Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. The Journal of Toxicological Sciences. 2015;40:329–338. doi: 10.2131/jts.40.329. [DOI] [PubMed] [Google Scholar]
- 41.Li D, Chen L, Zhao W, Hao J, An R. MicroRNA-let-7f-1 is induced by lycopene and inhibits cell proliferation and triggers apoptosis in prostate cancer. Molecular medicine reports. 2016;13:2708–2714. doi: 10.3892/mmr.2016.4841. [DOI] [PubMed] [Google Scholar]
- 42.Ghanbari R, et al. Simultaneous Underexpression of let-7a-5p and let-7f-5p microRNAs in Plasma and Stool Samples from Early Stage Colorectal Carcinoma. Biomarkers in Cancer. 2015;7:39–48. doi: 10.4137/BIC.S25252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Nakajima G, et al. Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer genomics & proteomics. 2006;3:317–324. [PMC free article] [PubMed] [Google Scholar]
- 44.Kumar MS, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sciences. 2008;105:3903–3908. doi: 10.1073/pnas.0712321105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Salvarredi LA, et al. 2-iodohexadecanal Inhibits thyroid cell growth in part through the induction of let-7f microRNA. Molecular and Cellular Endocrinology. 2015;414:224–232. doi: 10.1016/j.mce.2015.07.007. [DOI] [PubMed] [Google Scholar]
- 46.Huang, X. et al. Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer. Genetics and Molecular Research14, 16913-16920 (2015). [DOI] [PubMed]
- 47.Qian P, et al. Pivotal Role of Reduced let-7g/Expression in Breast Cancer Invasion and Metastasis. Cancer Research. 2011;71:6463–6474. doi: 10.1158/0008-5472.CAN-11-1322. [DOI] [PubMed] [Google Scholar]
- 48.Ji J, et al. Let-7g targets collagen type I α2 and inhibits cell migration in hepatocellular carcinoma. Journal of Hepatology. 2010;52:690–697. doi: 10.1016/j.jhep.2009.12.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Shimizu S, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. Journal of Hepatology. 2010;52:698–704. doi: 10.1016/j.jhep.2009.12.024. [DOI] [PubMed] [Google Scholar]
- 50.Shibata C, et al. Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Molecular and Cellular Therapies. 2013;1:5. doi: 10.1186/2052-8426-1-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Hua Z, et al. MiRNA-Directed Regulation of VEGF and Other Angiogenic Factors under Hypoxia. PLoS ONE. 2006;1:e116. doi: 10.1371/journal.pone.0000116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Chen W, Schuman E. Circular RNAs in brain and other tissues: a functional enigma. Trends in Neurosciences. 2016;39:597–604. doi: 10.1016/j.tins.2016.06.006. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.